Document:

Exhibit 4.2

Table of Contents

EXHIBIT 4.2

$325,000,000

2% CONVERTIBLE SENIOR NOTES DUE 2023

REGISTRATION RIGHTS AGREEMENT

Dated as of August 1, 2003

by and among

INVITROGEN CORPORATION

and

UBS SECURITIES LLC

CREDIT SUISSE FIRST BOSTON LLC

TABLE OF CONTENTS

									
		SECTION 1. DEFINITIONS
		SECTION 2. HOLDERS
		SECTION 3. SHELF REGISTRATION
		SECTION 4. REGISTRATION PROCEDURES
		SECTION 5. HOLDERS’ AGREEMENTS
		SECTION 6. REGISTRATION EXPENSES
		SECTION 7. INDEMNIFICATION AND CONTRIBUTION
		SECTION 8. RULE 144A AND RULE 144
		SECTION 9. MISCELLANEOUS
	EXHIBIT 4.1
	EXHIBIT 4.2
	EXHIBIT 4.3
	EXHIBIT 5.1
	EXHIBIT 5.2
	EXHIBIT 12.1
	EXHIBIT 23.3
	EXHIBIT 23.5
	EXHIBIT 25.1

Table of Contents

     This Registration Rights Agreement (this “Agreement”) is made and entered
into as of August 1, 2003 by and among Invitrogen Corporation, a Delaware
corporation (the “Company”), and UBS Securities LLC and Credit Suisse First
Boston LLC (each an “Initial Purchaser” and collectively, the “Initial
Purchasers”). The Company proposes to issue and sell to the Initial Purchasers
(the “Initial Placement”) $325,000,000 in aggregate principal amount of its 2%
Convertible Senior Notes due 2023 (the “Firm Convertible Notes”). The Company
also proposes to issue and sell to the Initial Purchasers not more than
$48,750,000 in aggregate principal amount of its 2% Convertible Senior Notes
due 2023 (the “Additional Convertible Notes” and, together with the Firm
Convertible Notes, the “Notes”). As an inducement to the Initial Purchasers to
enter into the purchase agreement, dated as of July 28, 2003 (the “Purchase
Agreement”), and in satisfaction of a condition to the Initial Purchasers’
obligations thereunder, the Company agrees with the Initial Purchasers, (i) for
the benefit of the Initial Purchasers and (ii) for the benefit of the holders
from time to time of the Notes whose names appear in the register maintained by
the Registrar in accordance with the provisions of the Indenture (as defined in
Section 1 hereof) (including the Initial Purchasers), as follows:

SECTION 1. DEFINITIONS

     Capitalized terms used herein without definition shall have their
respective meanings set forth in the Purchase Agreement. As used in this
Agreement, the following capitalized defined terms shall have the following
meanings:

     “Act” means the Securities Act of 1933, as amended, and the rules and
regulations of the Commission promulgated thereunder.

     “Affiliate” of any specified person means any other person which, directly
or indirectly, is in control of, is controlled by, or is under common control
with, such specified person. For purposes of this definition, control of a
person means the power, direct or indirect, to direct or cause the direction of
the management and policies of such person whether by contract or otherwise;
and the terms “controlling” and “controlled” have meanings correlative to the
foregoing.

     “Agreement” means this Registration Rights Agreement.

     “Closing Date” has the meaning set forth in the Purchase Agreement.

     “Commission” means the Securities and Exchange Commission.

     “Common Stock” means the common stock of the Company, par value $0.01 per
share, issuable upon the conversion of the Notes.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, and
the rules and regulations of the Commission promulgated thereunder.

     “Holder” has the meaning set forth in Section 2 hereof.

LA\1074162.6

 

Table of Contents

     “Indenture” means the Indenture, dated as of August 1, 2003 between the
Company and the Trustee, relating to the Notes, as the same may be amended from
time to time in accordance with the terms thereof.

     “Initial Placement” has the meaning set forth in the preamble hereto.

     “Majority Holders” means the Holders of a majority of the aggregate
principal amount of securities registered under a Shelf Registration Statement.

     “Prospectus” means the prospectus included in any Shelf Registration
Statement (including, without limitation, a prospectus that discloses
information previously omitted from a prospectus filed as part of an effective
registration statement in reliance upon Rule 430A under the Act), as amended or
supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of Transfer Restricted Securities covered by such Shelf
Registration Statement, and all amendments and supplements to the Prospectus,
including post-effective amendments.

     “Shelf Registration” means a registration effected pursuant to Section 3
hereof.

     “Shelf Registration Period” has the meaning set forth in Section 3 hereof.

     “Shelf Registration Statement” means a “shelf” registration statement of
the Company pursuant to the provisions of Section 3 hereof that covers some or
all of the Transfer Restricted Securities as applicable, on an appropriate form
under Rule 415 under the Act, or any similar rule that may be adopted by the
Commission, amendments and supplements to such registration statement,
including post-effective amendments, and in each case, including the Prospectus
contained therein, all exhibits thereto and all material incorporated therein
by reference.

     “Supplemental Delay Period” means any period commencing on the date of
receipt by a Holder of Transfer Restricted Securities of any notice from the
Company of the existence of any fact or event of the kind described in Section
4(b)(2) hereof and ending on the date of receipt by such Holder of an amended
or supplemented Shelf Registration Statement or Prospectus, as contemplated by
Section 4(h) hereof, or the receipt by such Holder of written notice from the
Company (the “Advice”) that the use of the Prospectus may be resumed, and the
receipt of copies of any additional or supplemental filings that are
incorporated by reference in the Prospectus.

     “Transfer Restricted Securities” means each Note and the Common Stock
issuable upon conversion thereof until (i) the date on which such Note or the
Common Stock issuable upon conversion thereof has been effectively registered
under the Act and disposed of in accordance with the Shelf Registration
Statement, (ii) the date on which such Note or Common Stock issuable upon
conversion thereof is distributed to the public pursuant to Rule 144 under the
Act (or any similar provision then in effect) or is salable pursuant to Rule
144(k) under the Act or (iii) the date on which such Note or the Common Stock
issuable upon conversion thereof ceases to be outstanding.

     “Trustee” means the trustee with respect to the Notes under the Indenture.

2

Registration Rights Agreement

LA\1074162.6

Table of Contents

     “Underwriter” means any underwriter of Notes in connection with an
offering thereof under a Shelf Registration Statement.

SECTION 2. HOLDERS

     A person is deemed to be a holder of Transfer Restricted Securities (each,
a “Holder”) whenever such person becomes the registered holder of such Transfer
Restricted Securities under the Indenture and includes broker-dealers that hold
Transfer Restricted Securities (i) as a result of market making activities and
other trading activities and (ii) which were acquired directly from the Company
or an Affiliate of the Company.

SECTION 3. SHELF REGISTRATION

     The Company shall within 90 days of the date of original issuance of the
Notes, file with the Commission and thereafter shall use its reasonable best
efforts to cause to be declared effective under the Act on or prior to 180 days
(plus any additional days allowed as a result of a Supplemental Delay Period)
after the date of original issuance of the Notes, a Shelf Registration
Statement relating to the offer and sale of the Transfer Restricted Securities
by the Holders from time to time in accordance with the methods of distribution
elected by such Holders and set forth in such Shelf Registration Statement.

     The Company shall use its reasonable best efforts to keep the Shelf
Registration Statement continuously effective in order to permit the Prospectus
forming part thereof to be usable by Holders for a period of two years from the
date of original issuance of the Notes or such shorter period that will
terminate when (i) all the Transfer Restricted Securities covered by the Shelf
Registration Statement have been sold pursuant to the Shelf Registration
Statement, (ii) the date on which, in the opinion of counsel to the Company,
all of the Transfer Restricted Securities then held by the Holders may be sold
by such Holders in the public United States securities markets in the absence
of a registration statement covering such sales or (iii) the date on which
there ceases to be outstanding any Transfer Restricted Securities (in any such
case, such period being called the “Shelf Registration Period”). The Company
shall be deemed not to have used its reasonable best efforts to keep the Shelf
Registration Statement effective during the requisite period if it voluntarily
takes any action that would result in Holders of Transfer Restricted Securities
covered thereby not being able to offer and sell such securities during that
period, unless (i) such action is required by applicable law, (ii) such action
is taken by the Company in good faith and for valid business reasons (not
including avoidance of the Company’s obligations hereunder), including the
acquisition or divestiture of assets, so long as the Company promptly
thereafter complies with the requirements of Section 4(h) hereof, if applicable
or (iii) such action is taken because of any fact or circumstance giving rise
to a Supplemental Delay Period.

SECTION 4. REGISTRATION PROCEDURES

     In connection with any Shelf Registration Statement, the following
provisions shall apply:

3

Registration Rights Agreement

LA\1074162.6

Table of Contents

     (a)  The Company shall ensure that (i) any Shelf Registration Statement and
any amendment thereto and any Prospectus forming part thereof and any amendment
or supplement thereto complies in all material respects with the Act and the
rules and regulations thereunder, (ii) any Shelf Registration Statement and any
amendment thereto does not, when it becomes effective, contain an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading and
(iii) any Prospectus forming part of any Shelf Registration Statement, and any
amendment or supplement to such Prospectus, does not include an untrue
statement of a material fact or omit to state a material fact necessary in
order to make the statements, in the light of the circumstances under which
they were made, not misleading.

     (b)  (1) The Company shall advise the Initial Purchasers and the Holders of
Transfer Restricted Securities named in any Shelf Registration Statement that
have provided in writing to the Company a telephone or facsimile number and
address for notices, and, if requested by the Initial Purchasers or any such
Holder, confirm such advice in writing when a Shelf Registration Statement and
any amendment thereto has been filed with the Commission and when the Shelf
Registration Statement or any post-effective amendment thereto has become
effective.

          (2) The Company shall advise the Initial Purchasers and the Holders of
Transfer Restricted Securities named in any Shelf Registration Statement, which
have provided in writing to the Company a telephone or facsimile number and
address for notices, and, if requested by the Initial Purchasers or any such
Holder, confirm such advice in writing:

		
	 	     (i) of any request by the Commission for amendments or supplements
to the Shelf Registration Statement or the Prospectus included therein or
for additional information;
	 
	 	     (ii) of the initiation by the Commission of proceedings relating to
a stop order suspending the effectiveness of the Shelf Registration
Statement;
	 
	 	     (iii) of the issuance by the Commission of any stop order suspending
the effectiveness of the Shelf Registration Statement;
	 
	 	     (iv) of the receipt by the Company of any notification with respect
to the suspension of the qualification of the securities included therein
for sale in any jurisdiction or the initiation or threatening of any
proceeding for such purpose; and
	 
	 	     (v) of the existence of any fact and the happening of any event
that, in the opinion of the Company, makes untrue any statement of a
material fact made in its Shelf Registration Statement, the Prospectus or
any amendment or supplement thereto or any document incorporated by
reference therein or requires the making of any changes in the Shelf
Registration Statement or the Prospectus so that, as of such date, the
statements therein are not misleading and do not omit to state a material
fact required to be stated therein or necessary to make the statements
therein (in the case of the Prospectus, in light of the circumstances
under which they were made) not misleading.

4

Registration Rights Agreement

LA\1074162.6

Table of Contents

     Such advice may be accompanied by an instruction to suspend the use of the
Prospectus until the requisite changes have been made.

     (c)  The Company shall use its best efforts to obtain the withdrawal of any
order suspending the effectiveness of any Shelf Registration Statement at the
earliest possible time.

     (d)  The Company shall use its best efforts to furnish to each selling
Holder named in any Shelf Registration Statement who so requests in writing and
who has provided to the Company an address for notices, without charge, at
least one conformed copy of such Shelf Registration Statement and any
post-effective amendment thereto, including financial statements and, if the
Holder so requests in writing, all exhibits and schedules (including those
incorporated by reference).

     (e)  The Company shall, during the Shelf Registration Period, deliver to
each Holder of Transfer Restricted Securities named in any Shelf Registration
Statement and who has provided to the Company an address for notices, without
charge, as many copies of the Prospectus (including each preliminary
Prospectus) contained in such Shelf Registration Statement and any amendment or
supplement thereto as such Holder may reasonably request; subject to any notice
by the Company in accordance with Section 5(b) hereof, the Company consents to
the use of the Prospectus or any amendment or supplement thereto by each of the
selling Holders for the purposes of offering and resale of the Transfer
Restricted Securities covered by the Prospectus in accordance with the
applicable regulations promulgated under the Act.

     (f)  Prior to any offering of Transfer Restricted Securities pursuant to
any Shelf Registration Statement, the Company shall register or qualify or
cooperate with the Holders of Transfer Restricted Securities named therein and
their respective counsel in connection with the registration or qualification
of such Transfer Restricted Securities for offer and sale under the securities
or blue sky laws of such jurisdictions of the United States as any such Holders
reasonably request in writing not later than the date that is five business
days prior to the date upon which this Agreement specifies that the Shelf
Registration Statement shall become effective; provided, however, that the
Company will not be required to qualify generally to do business in any
jurisdiction where it is not then so qualified or to take any action which
would subject it to general or unlimited service of process or to taxation in
any such jurisdiction where it is not then so subject.

     (g)  The Company shall endeavor to cooperate with the Holders of Transfer
Restricted Securities to facilitate the timely preparation and delivery of
certificates representing Transfer Restricted Securities to be sold pursuant to
any Shelf Registration Statement free of any restrictive legends and in such
denominations and registered in such names as Holders may request in writing at
least two business days prior to sales of securities pursuant to such Shelf
Registration Statement.

     (h)  Subject to 4(l), upon the occurrence of any event contemplated by
paragraph 4(b)(2)(v) hereof, the Company shall promptly prepare a
post-effective amendment to any Shelf Registration Statement or an amendment or
supplement to the related Prospectus or file any other required document so
that as thereafter delivered to purchasers of the Transfer Restricted

5

Registration Rights Agreement

LA\1074162.6

Table of Contents

Securities covered thereby, the Prospectus will not include an untrue
statement of a material fact or omit to state any material fact necessary to
make the statements therein, in the light of the circumstances under which they
were made, not misleading; provided that in the event of a material business
transaction (including, without limitation, pending negotiations relating to
such a transaction) which would, in the opinion of counsel to the Company,
require disclosure by the Company in the Shelf Registration Statement of
material non-public information for which the Company has a bona fide business
purpose for not disclosing, then for so long as such circumstances exist, the
Company shall not be required to prepare and file a supplement or
post-effective amendment hereunder.

     (i)  Not later than the effective date of any such Shelf Registration
Statement hereunder, the Company shall cause to be provided a CUSIP number for
the Notes registered under such Shelf Registration Statement, and provide the
applicable trustee with certificates for such Notes in a form eligible for
deposit with The Depository Trust Company.

     (j)  During the twelve-month period commencing after effectiveness of the
Shelf Registration Statement, the Company shall make generally available to its
security holders in a regular filing on Form 10-Q or 10-K an earnings statement
satisfying the provisions of Rule 158 (which need not be audited).

     (k)  The Company shall cause the Indenture to be qualified under the Trust
Indenture Act in a timely manner.

     (l)  The Company may require each Holder of Transfer Restricted Securities,
which are to be sold pursuant to any Shelf Registration Statement, to furnish
to the Company within 20 business days after written request for such
information has been made by the Company, such information regarding the Holder
and the distribution of such securities as the Company may from time to time
reasonably require for inclusion in such Shelf Registration Statement and such
other information as may be necessary or advisable in the reasonable opinion of
the Company and its counsel, in connection with such Shelf Registration
Statement. No Holder of Transfer Restricted Securities shall be entitled to
the benefit of any Special Interest (as set forth in the Notes) under the
Indenture and the Notes or be entitled to use the Prospectus unless and until
such Holder shall have furnished the information required by this Section 4(l)
and all such information required to be disclosed in order to make the
information previously furnished to the Company by such Holder not materially
misleading. For the purposes of this Section 4(l), upon receipt of information
regarding a Holder requiring the filing of a supplement or amendment to the
Prospectus, the Company shall be required to so amend or supplement the
Prospectus within five (5) business days from the earlier to occur of: (i)
Holders holding at least $5 million in face value of Notes having provided
information requiring the filing of such an amendment or supplement, or (ii)
fifteen (15) business days having elapsed from the receipt of such information.

     (m)  The Company shall, if requested, promptly incorporate in a Prospectus
supplement or post-effective amendment to a Shelf Registration Statement, such
information as the Majority Holders reasonably agree should be included therein
in order to effect their distribution of the Notes and shall make all required
filings of such Prospectus supplement or post-effective amendment as soon as
notified of the matters to be incorporated in such

6

Registration Rights Agreement

LA\1074162.6

Table of Contents

Prospectus supplement or
post-effective amendment; provided, however, that
the Company shall not be required to take any action pursuant to this Section
4(m) that would, in the opinion of counsel for the Company, violate applicable
law or to include information the disclosure of which at the time would have a
material adverse effect on the business or operations of the Company and/or its
subsidiaries, as determined in good faith by the Company.

     (n)  The Company shall enter into such agreements and take all other
reasonably appropriate actions in order to expedite or facilitate the
registration or the disposition of the Transfer Restricted Securities, and in
connection therewith, if an underwriting agreement is entered into, cause the
same to contain indemnification and contribution provisions and procedures no
less favorable than those set forth in Section 7 (or such other provisions and
procedures acceptable to the Majority Holders), with respect to all parties to
be indemnified pursuant to Section 7.

     (o)  The Company shall upon receipt of a reasonable request in writing
therefor:

		
	 	     (i) make reasonably available at reasonable times prior to the
effectiveness of the related Shelf Registration Statement for inspection
by representatives of the Holders of Transfer Restricted Securities to be
registered thereunder and any attorney, accountant or other agent
retained by such Holders, at the office where normally kept during normal
business hours, all financial and other records, pertinent corporate
documents and properties of the Company and its subsidiaries, and cause
the Company’s officers, directors and employees to supply all relevant
information reasonably requested by the Holders’ attorneys, accountants
or other agents in connection with any such Shelf Registration Statement
as is customary for similar due diligence examinations; provided,
however, that the foregoing inspection and information gathering shall be
coordinated by one counsel designated by the Holders and that such
persons shall first agree in writing with the Company that any
information that is designated in writing by the Company, in good faith,
as confidential at the time of delivery of such information shall be kept
confidential by such person, unless such disclosure is made in connection
with a court proceeding or required by law, or such information becomes
available to the public generally or through a third party without an
accompanying obligation of confidentiality;
	 
	 	     (ii) obtain opinions of counsel to the Company and updates thereof
(which counsel and opinions (in form, scope and substance) shall be
reasonably satisfactory to the Majority Holders), addressed to each
selling Holder named in the Shelf Registration Statement covering such
matters (in form, scope and substance) as those matters set forth in
Section 9(e) of the Purchase Agreement;
	 
	 	     (iii) obtain “cold comfort” letters (or, in the case of any person
that does not satisfy the conditions for receipt of a “cold comfort”
letter specified in Statement on Auditing Standards No. 72, an
“agreed-upon procedures letter”) and updates thereof from the independent
certified public accountants of the Company (and, if necessary, any other
independent certified public accountants of any subsidiary of the Company
or of any business acquired by the Company for which financial statements
and financial data are, or are required to be, included in the Shelf
Registration Statement), addressed to each selling Holder of Transfer
Restricted Securities registered thereunder and the

7

Registration Rights Agreement

LA\1074162.6

Table of Contents

		
	 	underwriters, if any, in customary form and covering matters of the
type customarily covered in “cold comfort” letters in connection with
primary underwritten offerings; and
	 
	 	     (iv) deliver such documents and certificates as may be reasonably
requested by the Majority Holders, including those to evidence compliance
with Section 4(h).

          The foregoing actions set forth in clauses (ii), (iii) and (iv) of this
Section 4(o) shall be performed upon the effectiveness of such Shelf
Registration Statement and the effectiveness of each post-effective amendment
thereto.

     (p)  The Company may offer securities of the Company other than the Notes
under the Shelf Registration Statement, except where such offer would conflict
with the terms of the Purchase Agreement.

SECTION 5. HOLDERS’ AGREEMENTS

     Each Holder of Transfer Restricted Securities severally but not jointly,
by the acquisition of such Transfer Restricted Securities, agrees:

     (a)  To furnish the information required to be furnished pursuant to
Section 4(l) hereof within the time period set forth therein.

     (b)  That upon receipt of a notice of the commencement of a Supplemental
Delay Period, it will keep the fact and content of such notice confidential,
forthwith discontinue disposition of its Transfer Restricted Securities
pursuant to the Shelf Registration Statement, and will not deliver any
Prospectus forming a part thereof until receipt of the amended or supplemented
Shelf Registration Statement or Prospectus, as applicable, as contemplated by
Section 4(h) hereof, or until receipt of the Advice. If a Supplemental Delay
Period should occur, the Shelf Registration Period shall be extended by the
number of days of which the Supplemental Delay Period is comprised; provided
that the Shelf Registration Period shall not be extended if the Company has
received an opinion of counsel (which counsel, if different from counsel to the
Company referred to in Section 9(e) of the Purchase Agreement, shall be
reasonably satisfactory to the Majority Holders of the Transfer Restricted
Securities named in the Shelf Registration Period and which opinion shall be in
writing) to the effect that the Transfer Restricted Securities can be freely
tradable without the continued effectiveness of the Shelf Registration
Statement.

     (c)  If so directed by the Company in a notice of the commencement of a
Supplemental Delay Period, each Holder of Transfer Restricted Securities will
deliver to the Company (at the Company’s expense) all copies, other than
permanent file copies then in such Holder’s possession, of the Prospectus
covering the Transfer Restricted Securities.

     (d)  Sales of such Transfer Restricted Securities pursuant to a Shelf
Registration Statement shall only be made in the manner set forth in such
currently effective Shelf Registration Statement.

SECTION 6. REGISTRATION EXPENSES

8

Registration Rights Agreement

LA\1074162.6

Table of Contents

     The Company shall bear all expenses incurred in connection with the
performance of its obligations under Sections 3 and 4 hereof and will reimburse
the Holders for the reasonable fees and disbursements of one firm or counsel
designated by the Majority Holders to act as counsel for the Holders in
connection with any Shelf Registration Statement. Notwithstanding the
foregoing or anything in this Agreement to the contrary, each Holder shall pay
all underwriting discounts and commission of any underwriters with respect to
any Transfer Restricted Securities sold by it.

SECTION 7. INDEMNIFICATION AND CONTRIBUTION

     (a)  The Company agrees to indemnify and hold harmless each Holder and each
person, if any, who controls such Holder within the meaning of the Act or the
Exchange Act (each Holder, and such controlling persons are referred to
collectively as the “Indemnified Parties”) from and against any losses, claims,
damages or liabilities, joint or several, or any actions in respect thereof
(including, but not limited to, any losses, claims, damages, liabilities or
actions relating to purchases and sales of the Securities) to which each
Indemnified Party may become subject under the Act, the Exchange Act or
otherwise, insofar as such losses, claims, damages, liabilities or actions
arise out of or are based upon any untrue statement or alleged untrue statement
of a material fact contained in the Shelf Registration Statement or Prospectus
including any document incorporated by reference therein, or in any amendment
or supplement thereto or in any preliminary prospectus relating to the Shelf
Registration, or arise out of, or are based upon, the omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and shall reimburse,
as incurred, the Indemnified Parties for any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such loss,
claim, damage, liability or action in respect thereof; provided, however, that
(i) the Company shall not be liable in any such case to the extent that such
loss, claim, damage or liability arises out of or is based upon any untrue
statement or alleged untrue statement or omission or alleged omission made in
the Shelf Registration Statement or Prospectus or in any amendment or
supplement thereto or in any preliminary prospectus relating to the Shelf
Registration in reliance upon and in conformity with written information
furnished to the Company by or on behalf of such Holder specifically for
inclusion therein and (ii) with respect to any untrue statement or omission or
alleged untrue statement or omission made in any preliminary prospectus
relating to the Shelf Registration Statement, the indemnity agreement contained
in this subsection (a) shall not inure to the benefit of any Holder from whom
the person asserting any such losses, claims, damages or liabilities purchased
the securities concerned, to the extent that a prospectus relating to such
securities was required to be delivered by such Holder under the Act in
connection with such purchase and any such loss, claim, damage or liability of
such Holder results from the fact that there was not sent or given to such
person, at or prior to the written confirmation of the sale of such securities
to such person, a copy of the final Prospectus if the Company had previously
furnished copies thereof to such Holder; provided further, however, that this
indemnity agreement will be in addition to any liability which the Company may
otherwise have to such Indemnified Party. The Company shall also indemnify
underwriters, their officers and directors and each person who controls such
underwriters within the meaning of the Act or the Exchange Act to the same
extent as provided above with respect to the indemnification of the Holders if
requested by such Holders.

9

Registration Rights Agreement

LA\1074162.6

Table of Contents

     (b)  Each Holder, severally and not jointly, will indemnify and hold
harmless the Company, its officers and directors and each person, if any, who
controls the Company within the meaning of the Act or the Exchange Act from and
against any losses, claims, damages or liabilities or any actions in respect
thereof, to which the Company or any such controlling person may become subject
under the Act, the Exchange Act or otherwise, insofar as such losses, claims,
damages, liabilities or actions arise out of or are based upon any untrue
statement or alleged untrue statement of a material fact contained in the Shelf
Registration Statement or Prospectus or in any amendment or supplement thereto
or in any preliminary prospectus relating to the Shelf Registration, or arise
out of or are based upon the omission or alleged omission to state therein a
material fact necessary to make the statements therein not misleading, but in
each case only to the extent that the untrue statement or omission or alleged
untrue statement or omission was made in reliance upon and in conformity with
written information furnished to the Company by or on behalf of such Holder
specifically for inclusion therein; and, subject to the limitation set forth
immediately preceding this clause, shall reimburse, as incurred, the Company
for any legal or other expenses reasonably incurred by the Company or any such
controlling person in connection with investigating or defending any loss,
claim, damage, liability or action in respect thereof. This indemnity
agreement will be in addition to any liability which such Holder may otherwise
have to the Company or any of its controlling persons.

     (c)  Promptly after receipt by an indemnified party under this Section 7 of
notice of the commencement of any action or proceeding (including a
governmental investigation), such indemnified party will, if a claim in respect
thereof is to be made against the indemnifying party under this Section 7,
notify the indemnifying party of the commencement thereof; but the omission so
to notify the indemnifying party will not, in any event, relieve the
indemnifying party from any obligations to any indemnified party other than the
indemnification obligation provided in paragraph (a) or (b) above. In case any
such action is brought against any indemnified party, and it notifies the
indemnifying party of the commencement thereof, the indemnifying party will be
entitled to participate therein and, to the extent that it may wish, jointly
with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel reasonably satisfactory to such indemnified party (who
shall not, except with the consent of the indemnified party, be counsel to the
indemnifying party), and after notice from the indemnifying party to such
indemnified party of its election so to assume the defense thereof the
indemnifying party will not be liable to such indemnified party under this
Section 7 for any legal or other expenses, other than reasonable costs of
investigation, subsequently incurred by such indemnified party in connection
with the defense thereof. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement of any pending
or threatened action in respect of which any indemnified party is or could have
been a party and indemnity could have been sought hereunder by such indemnified
party unless such settlement (i) includes an unconditional release of such
indemnified party from all liability on any claims that are the subject matter
of such action, and (ii) does not include a statement as to or an admission of
fault, culpability or a failure to act by or on behalf of any indemnified
party.

     (d)  If the indemnification provided for in this Section 7 is unavailable
or insufficient to hold harmless an indemnified party under subsections (a) or
(b) above, then each indemnifying party shall contribute to the amount paid or
payable by such indemnified party as a result of the losses, claims, damages or
liabilities (or actions in respect thereof) referred to in

10

Registration Rights Agreement

LA\1074162.6

Table of Contents

subsection (a) or (b) above in such proportion as is appropriate to
reflect the relative fault of the indemnifying party or parties on the one hand
and the indemnified party on the other in connection with the statements or
omissions that resulted in such losses, claims, damages or liabilities (or
actions in respect thereof) as well as any other relevant equitable
considerations. The relative fault of the parties shall be determined by
reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company on the one hand or
such Holder or such other indemnified party, as the case may be, on the other,
and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. The amount paid
by an indemnified party as a result of the losses, claims, damages or
liabilities referred to in the first sentence of this subsection (d) shall be
deemed to include any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any action or
claim which is the subject of this subsection (d). Notwithstanding any other
provision of this Section 7(d), the Holders shall not be required to contribute
any amount in excess of the amount by which the net proceeds received by such
Holders from the sale of the securities pursuant to the Shelf Registration
Statement exceeds the amount of damages which such Holders have otherwise been
required to pay by reason of such untrue or alleged untrue statement or
omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent
misrepresentation. For purposes of this paragraph (d), each person, if any,
who controls such indemnified party within the meaning of the Act or the
Exchange Act shall have the same rights to contribution as such indemnified
party and each person, if any, who controls the Company within the meaning of
the Act or the Exchange Act shall have the same rights to contribution as the
Company.

     (e)  The agreements contained in this Section 7 shall survive the sale of
the securities pursuant to the Shelf Registration Statement and shall remain in
full force and effect, regardless of any termination or cancellation of this
Agreement or any investigation made by or on behalf of any indemnified party.

SECTION 8. RULE 144A AND RULE 144

     The Company agrees with each Holder, for so long as any Transfer
Restricted Securities remain outstanding and during any period in which the
Company (i) is not subject to Section 13 or 15(d) of the Exchange Act, to make
available, upon request of any Holder, to such Holder or beneficial owner of
Transfer Restricted Securities in connection with any sale thereof and any
prospective purchaser of such Transfer Restricted Securities designated by such
Holder or beneficial owner, the information required by Rule 144A(d)(4) under
the Act in order to permit resales of such Transfer Restricted Securities
pursuant to Rule 144A, and (ii) is subject to Section 13 or 15 (d) of the
Exchange Act, to make all filings required thereby in a timely manner in order
to permit resales of such Transfer Restricted Securities pursuant to Rule 144.

SECTION 9. MISCELLANEOUS

     (a)  No Inconsistent Agreements. The Company has not, as of the date
hereof, entered into, nor shall it, on or after the date hereof, enter into,
any agreement with respect to its

11

Registration Rights Agreement

LA\1074162.6

Table of Contents

securities that is inconsistent with the rights granted to the Holders
herein or otherwise conflicts with the provisions hereof.

     (b)  Amendments and Waivers. The provisions of this Agreement, including
the provisions of this sentence, may not be amended, qualified, modified or
supplemented, and waivers or consents to departures from the provisions hereof
may not be given, unless the Company has obtained the written consent of the
Holders of at least a majority of the then outstanding aggregate principal
amount of Notes; provided, however, that with respect to any matter that
directly or indirectly affects the rights of any Initial Purchaser hereunder,
the Company shall obtain the written consent of each such Initial Purchaser
against which such amendment, qualification, supplement, waiver or consent is
to be effective. Notwithstanding the foregoing (except the foregoing proviso),
a waiver or consent to depart from the provisions hereof, with respect to a
matter, which relates exclusively to the rights of Holders whose securities are
being sold pursuant to a Shelf Registration Statement and does not directly or
indirectly affect the rights of other Holders, may be given by the Majority
Holders, determined on the basis of Notes being sold rather than registered
under such Shelf Registration Statement.

     (c)  Notices. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand-delivery, first-class
mail, telex, telecopier, or air courier guaranteeing overnight delivery:

		
	 	     (i) if to a Holder, at the most current address given by such holder
to the Company in accordance with the provisions of this Section 9(c),
which address initially is, with respect to each Holder, the address of
such Holder maintained by the registrar under the Indenture;
	 
	 	     (ii) with a copy in like manner to UBS Securities LLC;
	 
	 	     (iii) if to the Initial Purchasers, initially at the respective
addresses set forth in the Purchase Agreement; and
	 
	 	     (iv) if to the Company, initially at its address set forth in the
Purchase Agreement.

     All such notices and communications shall be deemed to have been duly
given when received.

     Upon the date of filing of a Shelf Registration Statement notice shall be
delivered to UBS Securities LLC on behalf of the Initial Purchasers (in the
form attached hereto as Exhibit A) and shall be addressed to: Attention:
Syndicate Department, 299 Park Avenue, New York, New York 10171.

     The Initial Purchasers or the Company by notice to the other may designate
additional or different addresses for subsequent notices or communications.

     (d)  Successors and Assigns. This Agreement shall inure to the benefit of,
and be binding upon, the successors and assigns of each of the parties hereto,
including, without the need for an express assignment or any consent by the
Company thereto, subsequent Holders of

12

Registration Rights Agreement

LA\1074162.6

Table of Contents

Notes. The Company hereby agrees to extend the benefits of this Agreement
to any Holder of Notes and any such Holder may specifically enforce the
provisions of this Agreement as if an original party hereto.

     (e)  Counterparts. This agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original, and all of which taken
together shall constitute one and the same agreement.

     (f)  Headings. The headings in this agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

     (g)  Governing Law. This agreement shall be governed by and construed in
accordance with the internal laws of the State of New York applicable to
agreements made and to be performed in said State (without reference to the
conflict of law rules thereof).

     (h)  Severability. In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstances, is held
invalid, illegal or unenforceable in any respect for any reason, the validity,
legality and enforceability of any such provision in every other respect and
the remaining provisions hereof shall not be in any way impaired or affected
thereby, it being intended that all of the rights and privileges of the parties
shall be enforceable to the fullest extent permitted by law.

     (i)  Notes Held by the Company, etc. Whenever the consent or approval of
Holders of a specified percentage of principal amount of Notes is required
hereunder, Notes held by the Company or its Affiliates (other than subsequent
Holders of Notes if such subsequent Holders are deemed to be Affiliates solely
by reason of their holdings of such Notes) shall not be counted in determining
whether such consent or approval was given by the Holders of such required
percentage.

     (j)  Entire Agreement. This Agreement is intended by the parties as a
final expression of their agreement and intended to be a complete and exclusive
statement of the agreement and understanding of the parties hereto with respect
to the subject matter contained herein. There are no restrictions, promises,
warranties or undertakings, other than those set forth or referred to herein
with respect to the registration rights granted with respect to the Transfer
Restricted Securities. This Agreement supersedes all prior agreements and
understandings between the parties with respect to such subject matter.

     (k)  Waiver of Jury Trial. Each of UBS (on behalf of the Initial
Purchasers) and the Company (on its behalf and, to the extent permitted by
applicable law, on behalf of its stockholders and affiliates) waives all right
to trial by jury in any action, proceeding or counterclaim (whether based upon
contract, tort or otherwise) in any way arising out of or relating to this
Agreement.

13

Registration Rights Agreement

LA\1074162.6

Table of Contents

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first written above.

	 	 	 	 	 
	 	 	
INVITROGEN CORPORATION
	 	 	 	 	 
	 	 	
By:
	 	
	 	 	
 	 	

	 	 	
Name:
	 	JOHN A. COTTINGHAM
	 	 	
Title:
	 	VP. GEN’L COUNSEL & SECY

Registration Rights Agreement

 

Table of Contents

UBS SECURITIES LLC

CREDIT SUISSE FIRST BOSTON LLC

By:  UBS SECURITIES LLC

	 	 	 
	
By:
	 	
	
 	 	

	 	 	Name: DANIEL H. KLAUSNER
	 	 	Title:   EXECUTIVE DIRECTOR
	 	 	 
	
By:
	 	
	
 	 	

	
 
	 	Name: SHIV VASISHT
	
 
	 	Title:   ASSOCIATE DIRECTOR

Registration Rights Agreement

 

Table of Contents

EXHIBIT A

NOTICE OF FILING OF

SHELF REGISTRATION STATEMENT

	 	 	 
	To:	 	
UBS Securities LLC
	 	 	
299 Park Avenue
	 	 	
New York, New York 10171
	 	 	
Attention: [          ]
	 	 	
Fax: (212)      -     
	 	 	
 
	From:	 	
Invitrogen Corporation
	 	 	
2% Convertible Senior Notes due 2023

	Date:	 	
     , 200

	 	 	
For your information only (NO ACTION REQUIRED):

Today,      ,
200    , we filed a Shelf Registration Statement with the
Securities and Exchange Commission.

4

Registration Rights Agreement

LA\1074162.6Exhibit 4.3

 

EXHIBIT 4.3

INVITROGEN CORPORATION

$325,000,000

Principal Amount

2% Convertible Senior Notes due 2023

Purchase Agreement

July 28, 2003

UBS SECURITIES LLC

CREDIT SUISSE FIRST BOSTON LLC

 

2% Convertible Senior Notes due 2023

INVITROGEN CORPORATION

PURCHASE AGREEMENT

July 28, 2003

UBS SECURITIES LLC

CREDIT SUISSE FIRST BOSTON LLC

c/o UBS Securities LLC

             299 Park Avenue

             New York, N.Y. 10171

Dear Sirs:

          Invitrogen Corporation, a Delaware corporation (the “Company”), proposes
to issue and sell to UBS SECURITIES LLC (“UBS”) and Credit Suisse First Boston
LLC (each an “Initial Purchaser” and, collectively, the “Initial Purchasers”)
an aggregate of $325,000,000 in principal amount of its 2% Convertible Senior
Notes due 2023 (the “Firm Notes”), subject to the terms and conditions set
forth herein. The Company also proposes to issue and sell to the Initial
Purchasers not more than an additional $48,750,000 principal amount of its 2%
Convertible Senior Notes due 2023 (the “Additional Notes”), if requested by the
Initial Purchasers as provided in Section 2 hereof. The Firm Notes and the
Additional Notes are herein collectively referred to as the
“Notes”. The Notes are to be issued pursuant to the provisions of an indenture (the “Indenture”),
to be dated as of the Closing Date (as defined below), between the Company, and
U.S. Bank National Association, as trustee (the “Trustee”), pursuant to which
the Notes, as provided therein, will be convertible at the option of the
holders thereof into shares of the Company’s common stock, par value $0.01 per
share (the “Common Stock”). The Notes and the Common Stock issuable upon
conversion thereof are herein collectively referred to as the
“Securities”. The Securities and the Indenture are more fully described in the Offering
Memorandum (as hereinafter defined). Capitalized terms used but not defined
herein shall have the meanings given to such terms in the Indenture.

     1.     Offering Memorandum. The Notes will be offered and sold to the Initial
Purchasers pursuant to one or more exemptions from the registration
requirements under the Securities Act of 1933, as amended (the “Act”). The
Company has prepared a preliminary offering memorandum, dated July 28, 2003
(the “Preliminary Offering Memorandum”) and a final offering memorandum, dated
July 28, 2003 (the “Offering Memorandum” and together with the Preliminary
Offering Memorandum and all other documents and reports incorporated therein by

1

Purchase Agreement

LA\1074155.8

 

reference, the
“Offering Document”), relating to the Notes. The Company’s Annual Report on
Form 10-K most recently filed with the Commission and all subsequent reports
which have been filed by the Company with the Commission or sent to
stockholders pursuant to the Exchange Act prior to the date hereof are
collectively referred to as the “Exchange Act Reports.”

     Upon original issuance thereof, and until such time as the same is no
longer required pursuant to the Indenture, the Notes (and all securities issued
in exchange therefor, in substitution thereof or upon conversion thereof) shall
bear a legend substantially as follows:

	 	 	“THIS SECURITY (OR ITS PREDECESSOR) WAS ORIGINALLY ISSUED IN A
TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES SECURITIES
ACT OF 1933 (THE “SECURITIES ACT”), AND THIS SECURITY AND THE SHARES OF
COMMON STOCK ISSUABLE UPON CONVERSION THEREOF MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN
APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF THIS SECURITY IS
HEREBY NOTIFIED THAT THE SELLER OF THIS SECURITY MAY BE RELYING ON THE
EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED
BY RULE 144A THEREUNDER.
	 
	 	 	THE HOLDER OF THIS SECURITY AGREES FOR THE BENEFIT OF THE COMPANY THAT
(A) THIS SECURITY AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION
THEREOF MAY BE OFFERED, RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY
(I) IN THE UNITED STATES TO A PERSON WHOM THE SELLER REASONABLY BELIEVES
IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT) IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A,
(II) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN ACCORDANCE
WITH RULE 904 UNDER THE SECURITIES ACT, (III) PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT PROVIDED BY RULE 144
THEREUNDER (IF AVAILABLE) OR (IV) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT, IN EACH OF CASES (I) THROUGH (IV) IN
ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED
STATES, AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT HOLDER IS REQUIRED
TO, NOTIFY ANY PURCHASER OF THIS SECURITY FROM IT OF THE RESALE
RESTRICTIONS REFERRED TO IN (A) ABOVE.
	 
	 	 	THE HOLDER OF THIS SECURITY IS ENTITLED TO THE BENEFITS OF A
REGISTRATION RIGHTS AGREEMENT (AS SUCH TERM IS DEFINED IN THE
INDENTURE REFERRED TO ON THE REVERSE HEREOF) AND, BY ITS
ACCEPTANCE HEREOF, AGREES TO BE BOUND BY AND TO COMPLY WITH THE
PROVISIONS OF SUCH REGISTRATION RIGHTS AGREEMENT.”

2

Purchase Agreement

LA\1074155.8

 

     2.     Agreements
to Sell and Purchase.

               (a) On the basis of the representations, warranties and covenants
contained in this Agreement, and subject to the terms and conditions contained
herein, the Company agrees to issue and sell to the Initial Purchasers, and the
Initial Purchasers agree, severally and not jointly, to purchase from the
Company, the principal amount of Firm Notes set forth opposite its name as set
forth on Schedule A hereto at a purchase price equal to 97.5% of the principal
amount thereof (the “Purchase Price”).

               (b) On the basis of the representations and warranties contained in this
Agreement, and subject to its terms and conditions, (i) the Company agrees to
issue and sell the Additional Notes and (ii) the Initial Purchasers shall have
a right, but not the obligation, to purchase, severally and not jointly, the
Additional Notes, from the Company at the Purchase Price. Additional Notes may
be purchased solely for the purpose of covering over-allotments made in
connection with the offering of the Firm Notes. The Initial Purchasers may
exercise their right to purchase Additional Notes in whole or in part from time
to time by giving written notice of such election to exercise this option not
later than 11 days after the Closing Date. UBS shall give any such notice on
behalf of the Initial Purchasers and such notice shall specify the aggregate
principal amount of Additional Notes to be purchased pursuant to such exercise
and the date for payment and delivery thereof. The purchase date specified in
any such notice shall be a business day (i) no earlier than the Closing Date
(as hereinafter defined) and (ii) two (2) business days after such notice has
been given. If any Additional Notes are to be purchased, each Initial
Purchaser, severally and not jointly, agrees to purchase from the Company the
principal amount of Additional Notes which bears the same proportion to the
total principal amount of Additional Notes to be purchased from the Company as
the principal amount of Firm Notes set forth opposite the name of such Initial
Purchaser in Schedule A bears to the total principal amount of Firm Notes.

     3.     Terms of Offering. The Initial Purchasers have advised the Company
that the Initial Purchasers will make offers (the “Exempt Resales”) of the
Notes purchased hereunder on the terms set forth in the Offering Memorandum, as
amended or supplemented, solely to persons whom the Initial Purchasers
reasonably believe to be “qualified institutional buyers” as defined in Rule
144A under the Act (“QIBs”) (such persons being referred to herein as the
“Eligible Purchasers”). The Initial Purchasers will offer the Notes to
Eligible Purchasers initially at a price equal to 100% of the principal amount
thereof (plus accrued interest, if applicable). Such price may be changed at
any time without notice.

     Holders (including subsequent transferees) of the Securities will have the
registration rights set forth in the registration rights agreement (the
“Registration Rights Agreement”), to be dated the Closing Date, in
substantially the form of Exhibit A hereto, for so long as such Securities
constitute “Transfer Restricted Securities” (as defined in the Registration
Rights Agreement). Pursuant to the Registration Rights Agreement, the Company
will agree to file with the Securities and Exchange Commission (the
“Commission”) under the circumstances set forth therein, a shelf registration
statement pursuant to Rule 415 under the Act (the “Registration Statement”)
relating
to the resale by certain holders of the Securities and to use its best
efforts to cause such Registration Statement to be declared and remain
effective and usable for the periods specified in the Registration Rights
Agreement. This Agreement, the Indenture, the Notes, and the Registration

3

Purchase Agreement

LA\1074155.8

 

Rights Agreement are hereinafter sometimes referred to collectively as the
“Operative Documents.”

     4.     Delivery
and Payment.

               (a) Delivery of, and payment of the Purchase Price for, the Firm Notes
shall be made at the offices of Gray Cary Ware & Freidenrich LLP, 4365
Executive Drive, Suite 1100, San Diego, California 92121-2189 or such other
location as may be mutually acceptable. Such delivery and payment shall be
made at 9:00 a.m. New York City time, on August 1, 2003 or at such other time
on the same date or such other date as shall be agreed upon by the Initial
Purchasers and the Company in writing. The time and date of such delivery and
the payment for the Firm Notes are herein called the “Closing
Date”.

               (b) Delivery of, and payment for, any Additional Notes to be purchased by
the Initial Purchasers shall be made at the offices of Gray Cary Ware &
Freidenrich LLP, 4365 Executive Drive, Suite 1100, San Diego, California
92121-2189 at 9:00 a.m. New York City time, on the date specified in the
exercise notice given by UBS pursuant to Section 2(b) or such other time on the
same or such other date as the Initial Purchasers and the Company shall agree
in writing. The time and date of delivery and payment for any Additional Notes
are hereinafter referred to as an “Option Closing Date.”

               (c) One or more of the Notes in definitive global form, registered in the
name of Cede & Co., as nominee of the Depository Trust Company
(“DTC”), having
an aggregate principal amount corresponding to the aggregate principal amount
of the Notes (collectively, the “Global Note”), shall be delivered by the
Company to the Initial Purchasers (or as the Initial Purchasers direct) in each
case with any transfer taxes thereon duly paid by the Company against payment
by the Initial Purchasers of the Purchase Price thereof by wire transfer in
same day funds to the order of the Company. The Global Note shall be made
available to the Initial Purchasers for inspection not later than 9:30 a.m.,
New York City time, on the business day immediately preceding the Closing Date.

     5.     Agreements
of the Company. The Company hereby agrees with the Initial
Purchasers as follows:

               (a) To advise the Initial Purchasers promptly and, if requested by the
Initial Purchasers, confirm such advice in writing, (i) of the issuance by any
state securities commission of any stop order suspending the qualification or
exemption from qualification of any Notes for offering or sale in any
jurisdiction designated by the Initial Purchasers pursuant to Section 5(d)
hereof, or the initiation of any proceeding by any state securities commission
or any other federal or state regulatory authority for such purpose and (ii) of
any proposal to amend or supplement the Offering Document and the Company will
not effect such amendment or supplementation without UBS’ consent, which
consent shall not be unreasonably withheld or delayed. If, at any time prior
to the completion of the resale of the Notes by the Initial Purchasers,
any event occurs as a result of which the Offering Document as then amended or
supplemented would include an untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading, the
Company promptly will notify UBS of such event and promptly will prepare, at
its own

4

Purchase Agreement

LA\1074155.8

 

expense, an amendment or supplement which will correct such statement
or omission. Neither UBS’ consent to, nor the Initial Purchasers’ delivery to
offerees or investors of, any such amendment or supplement shall constitute a
waiver of any of the conditions set forth in Section 9. The Company shall use
its best efforts to prevent the issuance of any stop order or order suspending
the qualification or exemption of any Notes under any state securities or Blue
Sky laws and, if at any time any state securities commission or other federal
or state regulatory authority shall issue an order suspending the qualification
or exemption of any Notes under any state securities or Blue Sky laws, the
Company shall use its best efforts to obtain the withdrawal or lifting of such
order at the earliest possible time.

               (b) To furnish the Initial Purchasers and those persons identified by the
Initial Purchasers to the Company as many copies of the Preliminary Offering
Memorandum and the Offering Memorandum, any documents incorporated by reference
therein, and any amendments or supplements thereto, as the Initial Purchasers
may reasonably request at any time prior to the completion of the resale of the
Notes by the Initial Purchasers. Subject to the Initial Purchasers’ compliance
with its representations and warranties and agreements set forth in Section 7
hereof, the Company consents to the use of the Preliminary Offering Memorandum
and the Offering Memorandum, any documents incorporated by reference therein,
and any amendments and supplements thereto required pursuant hereto, by the
Initial Purchasers in connection with Exempt Resales.

               (c) If, at any time prior to the completion of the resale of the Notes by
the Initial Purchasers, any event shall occur or condition shall exist as a
result of which, in the opinion of counsel to the Initial Purchasers, it
becomes necessary to amend or supplement the Offering Memorandum in order to
make the statements therein, in the light of the circumstances when such
Offering Memorandum is delivered to an Eligible Purchaser, not misleading, or
if, in the opinion of counsel to the Initial Purchasers, it is necessary to
amend or supplement the Offering Memorandum to comply with any applicable law,
forthwith to prepare an appropriate amendment or supplement to such Offering
Memorandum so that the statements therein, as so amended or supplemented, will
not, in the light of the circumstances when it is so delivered, be misleading,
or so that such Offering Memorandum will comply with applicable law, and to
furnish to the Initial Purchasers and such other persons as the Initial
Purchasers may designate such number of copies thereof as the Initial
Purchasers may reasonably request.

               (d) Prior to the sale of all Notes pursuant to Exempt Resales as
contemplated hereby, to cooperate with the Initial Purchasers and counsel to
the Initial Purchasers in connection with the registration or qualification of
the Notes for offer and sale to the Initial Purchasers and pursuant to Exempt
Resales under the securities or Blue Sky laws of such jurisdictions as the
Initial Purchasers may reasonably request and to continue such registration or
qualification in effect so long as required for Exempt Resales and to file such
consents to service of process or other documents as may be necessary in order
to effect such registration or qualification; provided, however, that the
Company shall not be required in connection therewith to
qualify as a foreign corporation in any jurisdiction in which it is not
now so qualified or to take any action that would subject it to general consent
to service of process or taxation other than as to matters and transactions
relating to the Preliminary Offering Memorandum, the Offering Memorandum or
Exempt Resales, in any jurisdiction in which it is not now so subject.

5

Purchase Agreement

LA\1074155.8

 

               (e) So long as the Notes are outstanding, (i) to mail or make generally
available as soon as practicable after the end of each fiscal year to the
record holders of the Notes a financial report of the Company and its
subsidiaries on a consolidated basis (and a similar financial report of all
unconsolidated subsidiaries, if any), all such financial reports to include a
consolidated balance sheet, a consolidated statement of operations, a
consolidated statement of cash flows and a consolidated statement of
shareholders’ equity as of the end of and for such fiscal year, together with
comparable information as of the end of and for the preceding year, certified
by the Company’s independent public accountants and (ii) to mail or make
generally available as soon as practicable after the end of each quarterly
period (except for the last quarterly period of each fiscal year) to such
holders, a consolidated balance sheet, a consolidated statement of operations
and a consolidated statement of cash flows (and similar financial reports of
all unconsolidated subsidiaries, if any) as of the end of and for such period,
and for the period from the beginning of such year to the close of such
quarterly period, together with comparable information for the corresponding
periods of the preceding year.

               (f) So long as the Notes are outstanding, to furnish to the Initial
Purchasers as soon as available, copies of all reports or other communications
furnished by the Company to its security holders or furnished to or filed with
the Commission or any national securities exchange on which any class of
securities of the Company is listed and such other publicly available
information concerning the Company and/or its subsidiaries as the Initial
Purchasers may reasonably request.

               (g) So long as any of the Notes remain outstanding and during any period
in which the Company is not subject to Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), to make available to any
holder of Securities in connection with any sale thereof and any prospective
purchaser of such Securities from such holder, the information (“Rule 144A
Information”) required by Rule 144A(d)(4) under the Act.

               (h) Whether or not the transactions contemplated in this Agreement are
consummated or this Agreement is terminated, to pay or cause to be paid all
reasonable expenses incident to the performance of the obligations of the
Company under this Agreement, including: (i) the reasonable fees, disbursements
and expenses of counsel to the Company and accountants of the Company in
connection with the sale and delivery of the Notes to the Initial Purchasers
and pursuant to Exempt Resales, and all other fees and expenses in connection
with the preparation, printing, filing and distribution of the Preliminary
Offering Memorandum, the Offering Memorandum and all amendments and supplements
to any of the foregoing (including financial statements), including the mailing
and delivering of copies thereof to the Initial Purchasers and persons
designated by them in the quantities specified herein, (ii) all costs and
expenses related to the transfer and delivery of the Notes to the Initial
Purchasers and pursuant to Exempt Resales, including any transfer or other
taxes payable thereon, (iii) all costs of printing or producing this Agreement,
the other Operative Documents and any other agreements or documents in
connection with the offering, purchase, sale or delivery of the Securities
(other than the fees, disbursements
and expenses of counsel to the Initial Purchasers, except as provided in
clause (iv) below), (iv) all expenses in connection with the registration or
qualification of the Securities for offer and sale under the securities or Blue
Sky laws of the several states and all costs of printing or producing any
preliminary and supplemental Blue Sky memoranda in connection therewith
(including the filing fees and reasonable fees and disbursements of counsel for
the Initial Purchasers in connection with

6

Purchase Agreement

LA\1074155.8

 

such registration or qualification
and memoranda relating thereto), (v) the cost of printing certificates
representing the Securities, (vi) all expenses and listing fees in connection
with the application for quotation of the Notes in the National Association of
Securities Dealers, Inc. (“NASD”) Automated
Quotation System - PORTAL
(“PORTAL”), (vii) the fees and expenses of the Trustee and the Trustee’s
counsel in connection with the Indenture and the Notes, (viii) the costs and
charges of any transfer agent, registrar and/or depositary (including DTC),
(ix) any fees charged by rating agencies for the rating of the Notes, (x) all
costs and expenses of the Registration Statement, as set forth in the
Registration Rights Agreement, (xi) all expenses and listing fees in connection
with the application for listing the Common Stock on the Nasdaq Stock Market’s
National Market (the “Nasdaq National Market”) and (xii) and all other costs
and expenses incident to the performance of the obligations of the Company
hereunder for which provision is not otherwise made in this Section.

               (i) To use its best efforts to effect the inclusion of the Notes in PORTAL
and to maintain the listing of the Notes on PORTAL for so long as the Notes are
outstanding.

               (j) To obtain the approval of DTC for “book-entry” transfer of the Notes,
and to comply with all of its agreements set forth in the representation
letters of the Company to DTC relating to the approval of the Notes by DTC for
“book-entry” transfer.

               (k) To cause the Common Stock issuable upon conversion of the Notes to be
duly included for quotation on the Nasdaq National Market prior to the Closing
Date subject to notice of official issuance. The Company will ensure that such
Common Stock remain included for quotation on the Nasdaq National Market or any
other national securities exchange following the Closing Date for so long as
any shares of Common Stock remain registered under the Exchange Act.

               (l) The Company shall not (i) offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, or otherwise transfer or
dispose of, directly or indirectly, or any shares of Common Stock or securities
convertible into or exchangeable or exercisable for any shares of Common Stock,
including options, warrants or other rights to purchase shares of Common Stock
or publicly disclose the intention to make any such offer, sale, pledge,
disposition or filing, or (ii) enter into any swap or other arrangement that
transfers, in whole or in part, any of the economic consequences associated
with the ownership of any Common Stock (regardless of whether any of the
transactions described in clause (i) or (ii) is to be settled by the delivery
of Common Stock, or such other securities, in cash or otherwise), except to the
Initial Purchasers pursuant to this Agreement, for a period of 90 days after
the Closing Date without the prior written consent of UBS. Notwithstanding the
foregoing, during such period (i) the Company may grant stock and stock options
pursuant to the Company’s existing stock option plans or other employee benefit
plans and may issue shares of Common Stock upon the exercise of such options
and make additional inducement grants of restricted stock to new employees,
(ii) the Company may issue
shares of Common Stock upon the exercise of an option or warrant or the
conversion of a security outstanding on the date hereof (including the Notes),
and (iii) the Company may issue shares of Common Stock in connection with
acquisitions of companies and businesses. Other than pursuant to the
Registration Rights Agreement, the Company also agrees not to file any
registration statement with the Commission with respect to any shares of Common
Stock, or any registration

7

Purchase Agreement

LA\1074155.8

 

statement relating to any U. S. dollar-denominated
debt securities issued or guaranteed by the Company and having a maturity of
more than one year from the date of issue, or any securities convertible into
or exercisable or exchangeable for Common Stock for a period of 90 days after
the Closing Date without the prior written consent of UBS. The Company shall,
prior to or concurrently with the execution of this Agreement, deliver an
agreement in the form of Schedule C-1 hereto or in the form of Schedule C-2
hereto (the form of which for each, individual signatory has been designated
and previously agreed to by the Initial Purchasers) executed by each of the
directors and officers of the Company listed on Schedule D hereto. The Company
agrees that with respect to the transfer of shares of Common Stock pursuant to
the agreements in the form of Schedule C-1 or Schedule C-2 by each of the
persons listed on Schedule D, the Company shall not consent to the transfer of
more than an aggregate of 500,000 shares of Common Stock with respect to all of
the persons listed on Schedule D on or prior to 90 days after the date of the
Offering Memorandum.

               (m) Not to sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in the Act) that would be
integrated with the sale of the Notes to the Initial Purchasers or pursuant to
Exempt Resales in a manner that would require the registration of any such sale
of the Notes under the Act.

               (n) Not to voluntarily claim, and to actively resist any attempts to
claim, the benefit of any usury laws against the holders of any Notes.

               (o) To comply with all of its agreements set forth in the Registration
Rights Agreement.

               (p) To use its best efforts to do and perform all things required or
necessary to be done and performed under this Agreement by it prior to the
Closing Date and to satisfy all conditions precedent to the delivery of the
Notes.

               (q) Until the earlier of (i) the second anniversary of the last Option
Closing Date and (ii) the first date of effectiveness of the registration
statement to be filed pursuant to the Registration Rights Agreement, the
Company will not, and will not permit any of its “controlled” “affiliates” (as
defined in Rule 405 under the Securities Act) to, resell any of the Notes or
the Common Stock underlying the Notes that constitute “restricted securities”
under Rule 144 that have been reacquired by any of them.

     6.     Representations,
Warranties and Agreements of the Company. As of the
date hereof, the Company represents and warrants to, and agrees with, the
Initial Purchasers that:

               (a) The Offering Document does not, and any supplement or amendment to it
will not, contain any untrue statement of a material fact or omit to state any
material fact required
to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading, except
that the representations and warranties contained in this paragraph (a) shall
not apply to statements in or omissions from the Offering Document (or any
supplement or amendment thereto) based upon information relating to the Initial
Purchasers furnished to the Company in writing by the Initial Purchasers
expressly for use therein as set forth in Section 8(b) hereof. The Initial
Purchasers shall not be deemed to have provided any

8

Purchase Agreement

LA\1074155.8

 

other information (and
therefore are not responsible for any statements or omissions related to such
other information). No stop order preventing the use of the Preliminary
Offering Memorandum or the Offering Memorandum, or any amendment or supplement
thereto, or any order asserting that any of the transactions contemplated by
this Agreement are subject to the registration requirements of the Act, has
been issued.

               (b) Each of the Company and its subsidiaries has been duly incorporated,
is validly existing as a corporation in good standing under the laws of its
jurisdiction of incorporation and has the corporate power and authority to
carry on its business as described in the Offering Document and to own, lease
and operate its properties, and each is duly qualified and is in good standing
as a foreign corporation authorized to do business in each jurisdiction in
which the nature of its business or its ownership or leasing of property
requires such qualification, except where the failure to be so qualified would
not have a material adverse effect on the business, prospects, financial
condition or results of operations of the Company and its subsidiaries, taken
as a whole (a “Material Adverse Effect”).

               (c) All outstanding shares of capital stock of the Company have been duly
authorized and validly issued and are fully paid, non-assessable and not
subject to any preemptive or similar rights.

               (d) The entities listed on Schedule B hereto are the only subsidiaries,
direct or indirect, of the Company. All of the outstanding shares of capital
stock of each of the Company’s subsidiaries have been duly authorized and
validly issued and are fully paid and non-assessable, and are owned by the
Company, directly or indirectly through one or more subsidiaries (except to the
extent that the Company’s direct or indirect ownership is less than 100% as set
forth on Schedule B hereto), free and clear of any security interest, claim,
lien, encumbrance or adverse interest of any nature (each, a “Lien”).

               (e) This Agreement has been duly authorized, executed and delivered by the
Company.

               (f) The Indenture has been duly authorized by the Company and, on the
Closing Date, will have been validly executed and delivered by the Company.
When the Indenture has been duly executed and delivered by the Company, the
Indenture will be a valid and binding agreement of the Company, enforceable
against the Company in accordance with its terms except as (i) the
enforceability thereof may be limited by bankruptcy, insolvency or similar laws
affecting creditors’ rights generally and (ii) rights of acceleration and the
availability of equitable remedies may be limited by equitable principles of
general applicability. On the Closing Date, the Indenture will conform in all
material respects to the requirements of the Trust Indenture Act of 1939, as
amended (the “TIA” or “Trust Indenture Act”), and the rules and regulations of
the Commission applicable to an indenture which is qualified thereunder.

               (g) The Notes have been duly authorized and, on the Closing Date, will
have been validly executed and delivered by the Company. When the Notes have
been issued, executed and authenticated in accordance with the provisions of
the Indenture and delivered to and paid for by the Initial Purchasers in
accordance with the terms of this Agreement, the Notes will be entitled to the
benefits of the Indenture and will be valid and binding obligations of the
Company,

9

Purchase Agreement

LA\1074155.8

 

enforceable in accordance with their terms except as (i) the
enforceability thereof may be limited by bankruptcy, insolvency or similar laws
affecting creditors’ rights generally and (ii) rights of acceleration and the
availability of equitable remedies may be limited by equitable principles of
general applicability. On the Closing Date, the Notes will conform as to legal
matters to the description thereof contained in the Offering Memorandum.

               (h) The Notes are convertible into Common Stock in accordance with the
terms of the Indenture; the shares of Common Stock initially issuable upon
conversion of the Notes have been duly authorized and reserved for issuance
upon such conversion and, when issued upon such conversion, will be validly
issued, fully paid and nonassessable, will conform to the description thereof
contained in the Offering Memorandum and will be duly authorized for listing on
the Nasdaq National Market, subject to notice of official issuance; the Company
has the authorized and outstanding capital stock as set forth in the Offering
Memorandum; and the stockholders of the Company or other holders of the
Company’s securities have no pre-emptive or similar rights with respect to the
Notes or the Common Stock issuable upon the Notes.

               (i) The Registration Rights Agreement has been duly authorized by the
Company and, on the Closing Date, will have been duly executed and delivered by
the Company. When the Registration Rights Agreement has been duly executed and
delivered, the Registration Rights agreement will be a valid and binding
agreement of the Company, enforceable against the Company in accordance with
its terms except as (i) the enforceability thereof may be limited by
bankruptcy, insolvency or similar laws affecting creditors’ rights generally
and (ii) rights of acceleration and the availability of equitable remedies may
be limited by equitable principles of general applicability. On the Closing
Date, the Registration Rights Agreement will conform as to legal matters to the
description thereof in the Offering Memorandum.

               (j) The authorized capital stock of the Company conforms as to legal
matters to the description thereof contained in the Offering Memorandum.

               (k) Neither the Company nor any of its subsidiaries is in violation of its
respective charter or by-laws or in default in the performance of any
obligation, agreement, covenant or condition contained in any indenture, loan
agreement, mortgage, lease or other agreement or instrument to which the
Company or any of its subsidiaries is a party or by which the Company or any of
its subsidiaries or their respective property is bound and that is material to
the Company and its subsidiaries, taken as a whole, except for such violations
or defaults which, singly or in the aggregate, would not have a Material
Adverse Effect.

               (l) The execution, delivery and performance of the Operative Documents by
the Company, compliance by the Company with all provisions hereof and thereof
and the consummation of the transactions contemplated hereby and thereby will
not (i) require any consent, approval, authorization or other order of, or
qualification with, any court or governmental body or agency (except such as
may be required under the securities or Blue Sky laws of the
various states), (ii) conflict with or constitute a breach of any of the
terms or provisions of, or a default under, the charter or by-laws of the
Company or any of its subsidiaries or any indenture, loan agreement, mortgage,
lease or other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries or
their respective property is bound and that is material to the Company and its
subsidiaries, taken as a whole, (iii)

10

Purchase Agreement

LA\1074155.8

 

violate or conflict with any applicable
law or any rule, regulation, judgment, order or decree of any court or any
governmental body or agency having jurisdiction over the Company, any of its
subsidiaries or their respective property, (iv) result in the imposition or
creation of (or the obligation to create or impose) a Lien under, any agreement
or instrument to which the Company or any of its subsidiaries is a party or by
which the Company or any of its subsidiaries or their respective property is
bound, or (v) result in the termination, suspension or revocation of any
Material Authorization (as defined below) of the Company or any of its
subsidiaries or result in any other impairment of the rights of the holder of
any such Material Authorization, except for such conflicts, breaches,
violations, terminations, suspensions, revocations, Liens or defaults which,
singly or in the aggregate, would not have a Material Adverse Effect.

               (m) Except as disclosed in the Company’s Quarterly Report on Form 10-Q for
the fiscal quarter ended March 31, 2003, there are no legal or governmental
proceedings pending or, to the Company’s knowledge, threatened to which the
Company or any of its subsidiaries is or could be (in the case of threatened
proceedings) a party or to which any of their respective property is or could
be (in the case of threatened proceeding) subject, except for such proceedings
which, if decided adversely to the Company, would not result, singly or in the
aggregate, in a Material Adverse Effect.

               (n) The Company and its subsidiaries have good and marketable title in fee
simple to all real property and good and marketable title to all personal
property owned by them which is material to the business of the Company and its
subsidiaries, in each case free and clear of all liens, encumbrances and
defects except such as are described in the Offering Memorandum or such as do
not materially affect the value of such property and do not interfere with the
use made and proposed to be made of such property by the Company and its
subsidiaries; and any real property and buildings held under lease by the
Company and its subsidiaries are held by them under valid, subsisting and
enforceable leases with such exceptions as are not material and do not
interfere with the use made and proposed to be made of such property and
buildings by the Company and its subsidiaries, in each case except as described
in the Offering Memorandum.

               (o) The Company and its subsidiaries own or possess, or can acquire on
reasonable terms, all patents, patent rights, licenses, inventions, copyrights,
know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks,
service marks and trade names (“Intellectual Property”) currently employed by
them in connection with the business now operated by them, except where the
failure to own or possess or otherwise be able to acquire such Intellectual
Property would not, singly or in the aggregate, have a Material Adverse Effect;
and neither the Company nor any of its subsidiaries has received any notice of
infringement of or conflict with asserted rights of others with respect to any
of such Intellectual Property which, singly or in the aggregate, if the subject
of an unfavorable decision, ruling or finding, would have a Material Adverse
Effect.

               (p) The Company and each of its subsidiaries are insured by insurers of
recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which they are
engaged; and neither the Company nor any of its subsidiaries (i) has received
notice from any insurer or agent of such insurer that substantial capital
improvements or other material expenditures will have to be made in order to
continue such insurance or (ii) has any reason to believe that it will not be
able to renew its existing insurance

11

Purchase Agreement

LA\1074155.8

 

coverage as and when such coverage expires
or to obtain similar coverage from similar insurers at a cost that would not
have a Material Adverse Effect.

               (q) Except as disclosed in the Offering Document or the Company’s
definitive Proxy Statement filed with the Commission on March 17, 2003, no
relationship, direct or indirect, exists between or among the Company or any of
its subsidiaries on the one hand, and the directors, officers, stockholders,
customers or suppliers of the Company or any of its subsidiaries on the other
hand, which would be required by the Act to be described in the Offering
Memorandum if the Offering Memorandum were a prospectus included in a
registration statement on Form S-1 file with the Commission.

               (r) The Company and each of its subsidiaries maintains a system of
internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management’s general or
specific authorizations; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability; (iii) access to
assets is permitted only in accordance with management’s general or specific
authorization; and (iv) the recorded accountability for assets is compared with
the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. Since March 31, 2003, neither the Company nor
any of its subsidiaries has made any change in its internal controls that would
be reportable in any filing under the Exchange Act pursuant to Item 307 of
Regulation S-K.

               (s) All material tax returns required to be filed by the Company and each
of its subsidiaries in any jurisdiction have been filed, other than those
filings being contested in good faith, and all material taxes, including
withholding taxes, penalties and interest, assessments, fees and other charges
due pursuant to such returns or pursuant to any assessment received by the
Company or any of its subsidiaries have been paid, other than those being
contested in good faith and for which adequate reserves have been provided.

               (t) Except for Item 17 on Schedule F hereto, neither the Company nor any
of its subsidiaries has violated any foreign, federal, state or local law or
regulation relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or
contaminants (“Environmental Laws”), any provisions of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”), or any provisions of the
Foreign Corrupt Practices Act or the rules and regulations promulgated
thereunder, except for such violations which, singly or in the aggregate, would
not have a Material Adverse Effect.

               (u) Each of the Company and its subsidiaries has such permits, licenses,
consents, exemptions, franchises, authorizations and other approvals (each, a
“Material Authorization”) of, and has made all filings with and notices to, all
governmental or regulatory authorities and self-regulatory organizations and
all courts and other tribunals, including without
limitation, under any applicable Environmental Laws, as are necessary to
own, lease, license and operate its respective properties and to conduct its
business, except where the failure to have any such Material Authorization or
to make any such filing or notice would not, singly or in the aggregate, have a
Material Adverse Effect. Each such Material Authorization is valid and in full
force and effect and each of the Company and its subsidiaries is in compliance
with all the terms and conditions thereof and with the rules and regulations of
the authorities and governing bodies

12

Purchase Agreement

LA\1074155.8

 

having jurisdiction with respect thereto; and no event has occurred (including,
without limitation, the receipt of any notice from any authority or governing
body) which allows or, after notice or lapse of time or both, would allow,
revocation, suspension or termination of any such Material Authorization or
results or, after notice or lapse of time or both, would result in any other
impairment of the rights of the holder of any such Material Authorization held
by the Company or its subsidiaries; and such Material Authorizations held by
the Company or its subsidiaries contain no restrictions that are burdensome to
the Company or any of its subsidiaries; except where such failure to be valid
and in full force and effect or to be in compliance, the occurrence of any such
event or the presence of any such restriction would not, singly or in the
aggregate, have a Material Adverse Effect.

               (v) There are no costs or liabilities associated with Environmental Laws
(including, without limitation, any capital or operating expenditures required
for clean-up, closure of properties or compliance with Environmental Laws or
any Material Authorization, any related constraints on operating activities and
any potential liabilities to third parties) which would, singly or in the
aggregate, have a Material Adverse Effect.

               (w) The accountants, Ernst & Young LLP, that have certified certain of the
financial statements and supporting schedules included in the Offering Document
are independent public accountants with respect to the Company, as required by
the Act and the Exchange Act. The historical financial statements, together
with related schedules and notes, set forth in the Offering Document comply as
to form in all material respects with the requirements applicable to
registration statements on Form S-1 under the Act.

               (x) The historical financial statements, together with related schedules
and notes forming part of or incorporated by reference into the Offering
Document (and any amendment or supplement thereto), present fairly the
consolidated financial position, results of operations and changes in financial
position of the Company and its subsidiaries on the basis stated or
incorporated by reference in the Offering Document at the respective dates or
for the respective periods to which they apply; such statements and related
schedules and notes have been prepared in accordance with generally accepted
accounting principles consistently applied throughout the periods involved,
except as disclosed therein; and the other financial and statistical
information and data set forth or incorporated by reference in the Offering
Document (and any amendment or supplement thereto) are, in all material
respects, accurately presented and prepared on a basis consistent with such
financial statements and the books and records of the Company.

               (y) The pro forma financial information included in the Offering Document
has been prepared on a basis consistent with the historical financial
statements of the Company and its subsidiaries and give effect to assumptions
used in the preparation thereof on a reasonable basis and in good faith and
present fairly the historical and proposed transactions contemplated by the
Preliminary Offering Memorandum and the Offering Memorandum.

               (z) The Company is not and, after giving effect to the offering and sale
of the Notes and the application of the net proceeds thereof as described in
the Offering Memorandum, will not be, an “investment company,” as such term is
defined in the Investment Company Act of 1940, as amended.

13

Purchase Agreement

LA\1074155.8

 

               (aa) Except as set forth in the Offering Document or on Schedule G hereto,
there are no contracts, agreements or understandings between the Company and
any person granting such person the right to require the Company to file a
registration statement under the Act with respect to any securities of the
Company or to require the Company to include such securities with the Notes
registered pursuant to any Registration Statement.

               (bb) Neither the Company nor any of its subsidiaries nor any agent thereof
acting on the behalf of them has taken, and none of them will take, any action
that might cause this Agreement or the issuance or sale of the Notes to violate
Regulation G (12 C.F.R. Part 207), Regulation T (12 C.F.R. Part 220),
Regulation U (12 C.F.R. Part 221) or Regulation X (12 C.F.R. Part 224) of the
Board of Governors of the Federal Reserve System.

               (cc) No “nationally recognized statistical rating organization” as such
term is defined for purposes of Rule 436(g)(2) under the Act (i) has imposed
(or has informed the Company that it is considering imposing) any condition
(financial or otherwise) on the Company’s retaining any rating assigned to the
Company, any securities of the Company or (ii) has indicated to the Company
that it is considering (a) the downgrading, suspension, or withdrawal of, or
any review for a possible change that does not indicate the direction of the
possible change in, any rating so assigned or (b) any change in the outlook for
any rating of the Company, or any securities of the Company.

               (dd) Since the respective dates as of which information is given in the
Offering Memorandum other than as set forth in the Offering Memorandum
(exclusive of any amendments or supplements thereto subsequent to the date of
this Agreement), (i) there has not occurred any material adverse change or, to
the knowledge of the Company, any development involving a prospective material
adverse change in the condition, financial or otherwise, or the earnings,
business, management or operations of the Company and its subsidiaries, taken
as a whole, (ii) there has not been any material adverse change or, to the
knowledge of the Company, any development involving a prospective material
adverse change in the capital stock or in the long-term debt of the Company or
any of its subsidiaries and (iii) neither the Company nor any of its
subsidiaries has incurred any material liability or obligation, direct or
contingent.

               (ee) Each of the Preliminary Offering Memorandum and the Offering
Memorandum, as of its date, contains all the information specified in, and
meeting the requirements of, Rule 144A(d)(4) under the Act.

               (ff) When the Notes are issued and delivered pursuant to this Agreement,
the Notes will not be of the same class (within the meaning of Rule 144A under
the Act) as any security of the Company that is listed on a national securities
exchange registered under Section 6 of the Exchange Act or that is quoted in a
United States automated inter-dealer quotation system.

               (gg) No form of general solicitation or general advertising (as defined in
Regulation D under the Act) was used by the Company, or any of its
representatives (other than the Initial Purchasers, as to whom the Company
makes no representation) in connection with the offer and sale of the Notes
contemplated hereby, including, but not limited to, articles, notices or other
communications published in any newspaper, magazine, or similar medium or
broadcast over

14

Purchase Agreement

LA\1074155.8

 

television or radio, or any seminar or meeting whose attendees have been
invited by any general solicitation or general advertising. No securities of
the same class as the Securities have been issued and sold by the Company
within the six-month period immediately prior to the date hereof.

               (hh) Prior to the effectiveness of any Registration Statement, the
Indenture is not required to be qualified under the TIA.

               (ii) No registration under the Act of the Securities is required for the
sale of the Securities to the Initial Purchasers as contemplated hereby or for
the Exempt Resales assuming the accuracy of the Initial Purchasers’
representations and warranties and agreements set forth in Section 7 hereof.

               (jj) The Company, together with its subsidiaries Invitrogen Limited,
Invitrogen K.K., Invitrogen New Zealand Limited, Invitrogen Canada, Inc. and
Invitrogen GmbH (the foregoing subsidiaries being collectively referred to as
the “Material Subsidiaries”), on a consolidated basis, represent (i) in excess
of 80% of the revenues of the Company and all of its subsidiaries on a
consolidated basis (the “Consolidated Revenues”) as set forth on the Company’s
Consolidated Statement of Operations for the period ended March 31, 2003
contained in the Quarterly Report on Form 10-Q filed by the Company with the
Commission on May 12, 2003 (the “First Quarter 10-Q”), and (ii) in excess of
90% of the total assets of the Company and its subsidiaries on a consolidated
basis (the “Consolidated Assets”) as set forth on the Company’s Consolidated
Balance Sheet as of March 31, 2003 contained in the First Quarter 10-Q. No
subsidiary of the Company, other than the Material Subsidiaries, on an
individual basis, represents (i) 5% or greater of the Consolidated Revenues as
set forth on the Company’s Consolidated Statement of Operations for the period
ended March 31, 2003 contained in the First Quarter 10-Q, or (ii) 5% or greater
of the Consolidated Assets as set forth on the Company’s Consolidated Balance
Sheet as of March 31, 2003 contained in the First Quarter 10-Q.

               (kk) Each certificate signed by any officer of the Company and delivered
to the Initial Purchasers or counsel for the Initial Purchasers pursuant to the
terms hereof shall be deemed to be a representation and warranty by the Company
to the Initial Purchasers as to the matters covered thereby.

               The Company acknowledges that the Initial Purchasers and, for purposes of
the opinions to be delivered to the Initial Purchasers pursuant to Section 9
hereof, counsel to the Company and counsel to the Initial Purchasers will rely
upon the accuracy and truth of the foregoing representations and hereby
consents to such reliance.

     7.     Initial
Purchasers’ Representations and Warranties. Each Initial
Purchaser, severally and not jointly, represents and warrants to, and agrees
with, the Company:

               (a) Such Initial Purchaser is either a QIB or an IAI, in either case, with
such knowledge and experience in financial and business matters as is necessary
in order to evaluate the merits and risks of an investment in the Notes.

               (b) Such Initial Purchaser (A) is not acquiring the Securities with a view
to any distribution thereof or with any present intention of offering or
selling any of the Securities in a transaction that would violate the Act or
the securities laws of any state of the United States or any

15

Purchase Agreement

LA\1074155.8

 

other applicable jurisdiction and (B) will be reoffering and reselling the
Securities only to QIBs in reliance on the exemption from the registration
requirements of the Act provided by Rule 144A.

               (c) Such Initial Purchaser agrees that no form of general solicitation or
general advertising (within the meaning of Regulation D under the Act) has been
or will be used by such Initial Purchaser or any of its representatives in
connection with the offer and sale of the Securities pursuant hereto,
including, but not limited to, articles, notices or other communications
published in any newspaper, magazine or similar medium or broadcast over
television or radio, or any seminar or meeting whose attendees have been
invited by any general solicitation or general advertising.

               (d) Such Initial Purchaser agrees that, in connection with Exempt Resales,
such Initial Purchaser will solicit offers to buy the Securities only from, and
will offer to sell the Securities only to, Eligible Purchasers. Each Initial
Purchaser further agrees that it will offer to sell the Securities only to, and
will solicit offers to buy the Securities only from (A) Eligible Purchasers
that such Initial Purchaser reasonably believes are QIBs that agree that (x)
the Securities purchased by them may be resold, pledged or otherwise
transferred within the time period referred to under Rule 144(k) (taking into
account the provisions of Rule 144(d) under the Act, if applicable) under the
Act, as in effect on the date of the transfer of such Securities, only (I) to
the Company or any of its subsidiaries, (II) to a person whom the seller
reasonably believes is a QIB purchasing for its own account or for the account
of a QIB in a transaction meeting the requirements of Rule 144A under the Act,
(III) in an offshore transaction (as defined in Rule 902 under the Act) meeting
the requirements of Rule 904 of the Act, (IV) in a transaction meeting the
requirements of Rule 144 under the Act, (V) to an Accredited Institution that,
prior to such transfer, furnishes the Trustee a signed letter containing
certain representations and agreements relating to the registration of transfer
of such Securities and, if requested by the Company, an opinion of counsel
acceptable to the Company that such transfer is in compliance with the Act,
(VI) in accordance with another exemption from the registration requirements of
the Act (and based upon an opinion of counsel acceptable to the Company) or
(VII) pursuant to an effective registration statement and, in each case, in
accordance with the applicable securities laws of any state of the United
States or any other applicable jurisdiction and (y) they will deliver to each
person to whom such Securities or an interest therein is transferred a notice
substantially to the effect of the foregoing.

               (e) Such Initial Purchaser agrees that it will not offer, sell or deliver
any of the Securities in any jurisdiction outside the United States except
under circumstances that will result in compliance with the applicable laws
thereof, and that it will take at its own expense whatever action is required
to permit its purchase and resale of the Securities in such jurisdictions.
Such Initial Purchaser understands that no action has been taken to permit a
public offering in any jurisdiction outside the United States where action
would be required for such purpose.

               Each Initial Purchaser acknowledges that the Company, for purposes of the
opinions to be delivered to each Initial Purchaser pursuant to Section 9
hereof, counsel to the Company and counsel to the Initial Purchasers will rely
upon the accuracy and truth of the foregoing representations and each Initial
Purchaser hereby consents to such reliance.

     8.     Indemnification
and Contribution.

16

Purchase Agreement

LA\1074155.8

 

               (a) The Company agrees to indemnify, defend and hold harmless each Initial
Purchaser, its partners, directors and officers, and any person who controls
any Initial Purchaser within the meaning of Section 15 of the Act or Section 20
of the Exchange Act, and the successors and assigns of all of the foregoing
persons, from and against any loss, damage, expense, liability or claim
(including the reasonable cost of investigation) which, jointly or severally,
any such Initial Purchaser or any such person may incur under the Act, the
Exchange Act, the common law or otherwise, insofar as such loss, damage,
expense, liability or claim arises out of or is based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in the
Offering Document or any amendment or supplement thereto or arises out of or is
based upon any omission or alleged omission to state a material fact required
to be stated therein or necessary to make the statements made therein not
misleading, except insofar as any such loss, damage, expense, liability or
claim arises out of or is based upon any untrue statement or alleged untrue
statement of a material fact contained in and in conformity with information
concerning such Initial Purchaser furnished in writing by or on behalf of such
Initial Purchaser through UBS to the Company expressly for use in such Offering
Document or arises out of or is based upon any omission or alleged omission to
state a material fact in connection with such information required to be stated
in such Offering Document or necessary to make such information not misleading
or (ii) any untrue statement or alleged untrue statement made by the Company in
Section 6 hereof or the failure by the Company to perform when and as required
any agreement or covenant contained herein.

               If any action, suit or proceeding (each, a “Proceeding”) is brought
against an Initial Purchaser or any such person in respect of which indemnity
may be sought against the Company pursuant to the foregoing paragraph, such
Initial Purchaser or such person shall promptly notify the Company in writing
of the institution of such Proceeding and the Company shall assume the defense
of such Proceeding, including the employment of counsel reasonably satisfactory
to such indemnified party and payment of all fees and expenses; provided,
however, that the omission to so notify the Company shall not relieve the
Company from any liability which the Company may have to any Initial Purchaser
or any such person or otherwise. Such Initial Purchaser or such person shall
have the right to employ its or their own counsel in any such case, but the
fees and expenses of such counsel shall be at the expense of such Initial
Purchaser or of such person unless the employment of such counsel shall have
been authorized in writing by the Company in connection with the defense of
such Proceeding or the Company shall not have, within a reasonable period of
time in light of the circumstances, employed counsel to have charge of the
defense of such Proceeding or such indemnified party or parties shall have
reasonably concluded that there may be defenses available to it or them which
are different from, additional to or in conflict with those available to the
Company (in which case the Company shall not have the right to direct the
defense of such Proceeding on behalf of the indemnified party or parties, but
the Company may employ counsel and participate in the defense thereof), in any
of which events such reasonable fees and expenses shall be borne by the Company
and paid as incurred (it being understood, however, that the Company shall not
be liable for the expenses of more than one separate counsel (in addition to
any local counsel) in any one Proceeding or series of related Proceedings in
the same jurisdiction representing the indemnified parties who are parties to
such Proceeding). The Company shall not be liable for any settlement of any
Proceeding effected without its written consent but if settled with the written
consent of the Company, the Company agrees to indemnify and hold harmless any
Initial Purchaser and any such person from and against any loss or liability by
reason of such settlement. Notwithstanding the foregoing sentence, if at any

17

Purchase Agreement

LA\1074155.8

 

time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel as
contemplated by the second sentence of this paragraph, then the indemnifying
party agrees that it shall be liable for any settlement of any Proceeding
effected without its written consent if (i) such settlement is entered into
more than 60 business days after receipt by such indemnifying party of the
afore-said request, (ii) such indemnifying party shall not have fully
reimbursed the indemnified party in accordance with such request prior to the
date of such settlement and (iii) such indemnified party shall have given the
indemnifying party at least 30 days’ prior notice of its intention to settle.
No indemnifying party shall, without the prior written consent of the
indemnified party, effect any settlement of any pending or threatened
Proceeding in respect of which any indemnified party is or could have been a
party and indemnity could have been sought hereunder by such indemnified party,
unless such settlement includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such
Proceeding and does not include an admission of fault, culpability or a failure
to act, by or on behalf of such indemnified party.

               (b) Each Initial Purchaser severally agrees to indemnify, defend and hold
harmless the Company, its directors and officers, and any person who controls
the Company within the meaning of Section 15 of the Act or Section 20 of the
Exchange Act, and the successors and assigns of all of the foregoing persons,
from and against any loss, damage, expense, liability or claim (including the
reasonable cost of investigation) which, jointly or severally, the Company or
any such person may incur under the Act, the Exchange Act, the common law or
otherwise, insofar as such loss, damage, expense, liability or claim arises out
of or is based upon any untrue statement or alleged untrue statement of a
material fact contained in and in conformity with information furnished in
writing by or on behalf of such Initial Purchaser through UBS to the Company
expressly for use in the Offering Document or any amendment or supplement
thereto, or arises out of or is based upon any omission or alleged omission to
state a material fact in connection with such information required to be stated
in such Offering Document or necessary to make such information not misleading,
it being understood and agreed that the only such information furnished by any
Initial Purchaser consists of the following information in the Offering
Document furnished on behalf of each Initial Purchaser: under the caption “Plan
of Distribution” paragraphs three, eleven and thirteen; provided, however, that
the Initial Purchasers shall not be liable for any losses, claims, damages or
liabilities arising out of or based upon the Company’s failure to perform its
obligations under Section 5(a) of this Agreement..

               If any Proceeding is brought against the Company or any such person in
respect of which indemnity may be sought against any Initial Purchaser pursuant
to the foregoing paragraph, the Company or such person shall promptly notify
such Initial Purchaser in writing of the institution of such Proceeding and
such Initial Purchaser shall assume the defense of such Proceeding, including
the employment of counsel reasonably satisfactory to such indemnified party and
payment of all fees and expenses; provided, however, that the omission to so
notify such Initial Purchaser shall not relieve such Initial Purchaser from any
liability which such Initial Purchaser may have to the Company or any such
person or otherwise. The Company or such person shall have the right to employ
its own counsel in any such case, but the fees and expenses of such counsel
shall be at the expense of the Company or such person unless the employment of
such counsel shall have been authorized in writing by such Initial Purchaser in
connection with the defense of such Proceeding or such Initial Purchaser shall
not have, within a reasonable period of time in light of the circumstances,
employed counsel to defend such Proceeding or such

18

Purchase Agreement

LA\1074155.8

 

indemnified party or parties shall have reasonably concluded that there
may be defenses available to it or them which are different from or additional
to or in conflict with those available to such Initial Purchaser (in which case
such Initial Purchaser shall not have the right to direct the defense of such
Proceeding on behalf of the indemnified party or parties, but such Initial
Purchaser may employ counsel and participate in the defense thereof but the
fees and expenses of such counsel shall be at the expense of such Initial
Purchaser), in any of which events such fees and expenses shall be borne by
such Initial Purchaser and paid as incurred (it being understood, however, that
such Initial Purchaser shall not be liable for the expenses of more than one
separate counsel (in addition to any local counsel) in any one Proceeding or
series of related Proceedings in the same jurisdiction representing the
indemnified parties who are parties to such Proceeding). No Initial Purchaser
shall be liable for any settlement of any such Proceeding effected without the
written consent of such Initial Purchaser but if settled with the written
consent of such Initial Purchaser, such Initial Purchaser agrees to indemnify
and hold harmless the Company and any such person from and against any loss or
liability by reason of such settlement. Notwithstanding the foregoing
sentence, if at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of
counsel as contemplated by the second sentence of this paragraph, then the
indemnifying party agrees that it shall be liable for any settlement of any
Proceeding effected without its written consent if (i) such settlement is
entered into more than 60 business days after receipt by such indemnifying
party of the aforesaid request, (ii) such indemnifying party shall not have
reimbursed the indemnified party in accordance with such request prior to the
date of such settlement and (iii) such indemnified party shall have given the
indemnifying party at least 30 days’ prior notice of its intention to settle.
No indemnifying party shall, without the prior written consent of the
indemnified party, effect any settlement of any pending or threatened
Proceeding in respect of which any indemnified party is or could have been a
party and indemnity could have been sought hereunder by such indemnified party,
unless such settlement includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such
Proceeding or does not include an admission of fault, culpability or a failure
to act, by or on behalf of such indemnified party.

               (c) If the indemnification provided for in this Section 8 is unavailable
to an indemnified party under subsections (a) and (b) of this Section 8 or
insufficient to hold an indemnified party harmless in respect of any losses,
damages, expenses, liabilities or claims referred to therein, then each
applicable indemnifying party shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, damages, expenses,
liabilities or claims (i) in such proportion as is appropriate to reflect the
relative benefits received by the Company on the one hand and the Initial
Purchasers on the other hand from the offering of the Notes or (ii) if the
allocation provided by clause (i) above is not permitted by applicable law, in
such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company on
the one hand and of the Initial Purchasers on the other in connection with the
statements or omissions which resulted in such losses, damages, expenses,
liabilities or claims, as well as any other relevant equitable considerations.
The relative benefits received by the Company on the one hand and the Initial
Purchasers on the other shall be deemed to be in the same respective
proportions as the total proceeds from the offering (net of underwriting
discounts and commissions but before deducting expenses) received by the
Company and the total underwriting discounts and commissions received by the
Initial Purchasers, bear to the aggregate public offering price of the Notes.
The relative fault of the Company on the one hand and of the Initial Purchasers
on the other shall be determined by reference to, among other

19

Purchase Agreement

LA\1074155.8

 

things, whether the untrue statement or alleged untrue statement of a
material fact or omission or alleged omission relates to information supplied
by the Company or by the Initial Purchasers and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission. The amount paid or payable by a party as a result of
the losses, damages, expenses, liabilities and claims referred to in this
subsection shall be deemed to include any legal or other fees or expenses
reasonably incurred by such party in connection with investigating, preparing
to defend or defending any Proceeding.

               (d) The Company and the Initial Purchasers agree that it would not be just
and equitable if contribution pursuant to this Section 8 were determined by pro
rata allocation (even if the Initial Purchasers were treated as one entity for
such purpose) or by any other method of allocation that does not take account
of the equitable considerations referred to in subsection (c) above.
Notwithstanding the provisions of this Section 8, no Initial Purchaser shall be
required to contribute any amount in excess of the amount by which the total
price at which the Notes underwritten by such Initial Purchaser and distributed
to the public were offered to the public exceeds the amount of any damage which
such Initial Purchaser has otherwise been required to pay by reason of such
untrue statement or alleged untrue statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Initial Purchasers’
obligations to contribute pursuant to this Section 8 are several in proportion
to their respective underwriting commitments and not joint.

               (e) The indemnity and contribution agreements contained in this Section 8
and the covenants, warranties and representations of the Company contained in
this Agreement shall remain in full force and effect regardless of any
investigation made by or on behalf of any Initial Purchaser, its partners,
directors or officers or any person (including each partner, officer or
director of such person) who controls any Initial Purchaser within the meaning
of Section 15 of the Act or Section 20 of the Exchange Act, or by or on behalf
of the Company, its directors or officers or any person who controls the
Company within the meaning of Section 15 of the Act or Section 20 of the
Exchange Act, and shall survive any termination of this Agreement or the
issuance and delivery of the Notes. The Company and each Initial Purchaser
agree promptly to notify each other of the commencement of any Proceeding
against it and, in the case of the Company, against any of the Company’s
officers or directors in connection with the issuance and sale of the Notes, or
in connection with the Offering Document.

     9.     Conditions
of Initial Purchaser’s Obligations. The several obligations
of the Initial Purchasers to purchase the Firm Notes under this Agreement on
the Closing Date and the Additional Notes, if any, on any Option Closing Date
are subject to the satisfaction of each of the following conditions.

               (a) All the representations and warranties of the Company contained in
this Agreement shall be true and correct on the Closing Date, or on each Option
Closing Date, if any, with the same force and effect as if made on and as of
the Closing Date or on each Option Closing Date, if any.

               (b) On or after the date hereof, (i) there shall not have occurred any
downgrading, suspension or withdrawal of, nor shall any notice have been given
of any potential or

20

Purchase Agreement

LA\1074155.8

 

intended downgrading, suspension or withdrawal of, or of any review (or of
any potential or intended review) for a possible change that does not indicate
the direction of the possible change in, any rating of the Company or any
securities of the Company (including, without limitation, the placing of any of
the foregoing ratings on credit watch with negative or developing implications
or under review with an uncertain direction) by any “nationally recognized
statistical rating organization” as such term is defined for purposes of Rule
436(g)(2) under the Act, (ii) there shall not have occurred any change, nor
shall any notice have been given of any potential or intended change, in the
outlook for any rating of the Company or any securities of the Company by any
such rating organization and (iii) no such rating organization shall have given
notice that it has assigned (or is considering assigning) a lower rating to the
Notes than that on which the Notes were marketed.

               (c) Since the respective dates as of which information is given in the
Offering Memorandum other than as set forth in the Offering Memorandum
(exclusive of any amendments or supplements thereto subsequent to the date of
this Agreement), (i) there shall not have occurred any change or any
development involving a prospective change in the condition, financial or
otherwise, or the earnings, business, management or operations of the Company
and its subsidiaries, taken as a whole, (ii) there shall not have been any
change or any development involving a prospective change in the capital stock
or in the long-term debt of the Company or any of its subsidiaries and (iii)
neither the Company nor any of its subsidiaries shall have incurred any
liability or obligation, direct or contingent, the effect of which, in any such
case described in clause 9(c)(i), 9(c)(ii) or 9(c)(iii), in UBS’ judgment, is
material and adverse and, in UBS’ judgment, makes it impracticable to market
the Securities on the terms and in the manner contemplated in the Offering
Memorandum.

               (d) You shall have received on the Closing Date a certificate, dated the
Closing Date, and on an Option Closing Date, if any, dated such Option Closing
Date, signed by Gregory T. Lucier and C. Eric Winzer, in their capacities as
President and Chief Executive Officer, and Chief Financial Officer,
respectively, of the Company, confirming the matters set forth in Sections
6(dd), 9(a) and 9(b) and stating that the Company has complied with all the
agreements and satisfied all of the conditions herein contained and required to
be complied with or satisfied on or prior to the Closing Date or Option Closing
Date, as the case may be.

               (e) (A) You shall have received on the Closing Date and each Option
Closing Date, if any, an opinion (satisfactory to you and counsel for the
Initial Purchasers), dated the Closing Date or such Option Closing Date, as the
case may be, of Gray Cary Ware & Freidenrich LLP, counsel for the Company, to
the effect that:

		
	 	                (i) the Company has been duly incorporated, is validly existing as a
corporation in good standing under the laws of its jurisdiction of
incorporation and has the corporate power and authority to carry on its
business as described in the Offering Document and to own, lease and
operate its properties;

		
	 	                (ii) the Notes and the Indenture have been duly authorized, executed
and delivered by the Company;

21

Purchase Agreement

LA\1074155.8

 

		
	 	                (iii) the Notes are convertible into shares of Common Stock in
accordance with the terms of the Indenture; the shares of Common Stock
initially issuable upon conversion of the Notes have been duly authorized
and reserved for issuance upon such conversion and, when issued upon such
conversion, will be validly issued, fully paid and nonassessable, will
conform to the description thereof contained in the Offering Memorandum;
the Company has filed with the Nasdaq National Market a “Notification
Form: Listing of Additional Shares” (the “Notification”) with respect to
the Common Stock initially issuable upon conversion of the Notes; the
Company has been advised by the staff of Nasdaq that the Notification was
deemed complete and that no additional information is required by Nasdaq
with respect to listing the Common Stock initially issuable upon
conversion of the Notes on the Nasdaq National Market and has not
received any notification to the contrary from Nasdaq; the Company has
the authorized capital stock as set forth in the Offering Memorandum; and
the stockholders of the Company have no pre-emptive or, to the knowledge
of such counsel, similar rights with respect to the Notes or the Common
Stock issuable upon the conversion of the Notes;

		
	 	                (iv) this Agreement has been duly authorized, executed and delivered
by the Company;

		
	 	                (v) The Registration Rights Agreement has been duly authorized,
executed and delivered by the Company and is a valid and binding
agreement of the Company enforceable against the Company in accordance
with its terms, except as (x) the enforceability thereof may be limited
by bankruptcy, insolvency or similar laws affecting creditors’ rights
generally and (y) rights of acceleration and the availability of
equitable remedies may be limited by equitable principles of general
applicability;

		
	 	                (vi) the statements under the captions “Description of Notes,”
“Description of Capital Stock” and “Certain United States Federal Income
Tax Considerations” in the Offering Memorandum, insofar as such
statements constitute a summary of the legal matters or documents
referred to therein, fairly present in all material respects such legal
matters and documents;

		
	 	                (vii) the execution, delivery and performance of this Agreement and
the other Operative Documents by the Company, the compliance by the
Company with all provisions hereof and thereof and the consummation of
the transactions contemplated hereby and thereby will not: (i) require
any consent, approval, Material Authorization or other order of, or
qualification with, any court or governmental body or agency (except such
as may be required under the securities or Blue Sky laws of the various
states or for filings required by the Registration Rights Agreement),
(ii) conflict with or constitute a breach of any of the terms or
provisions of, or a default under, the charter or by-laws of the Company
or any of the agreements set forth on Schedule E hereto (the “Material
Contracts”), (iii) violate or conflict with any applicable law or any
rule or regulation, or, to such counsel’s knowledge, any existing
judgment, order or decree of any court or any governmental body or agency
having jurisdiction over the Company or its property, (iv) result in the
imposition or creation of (or the obligation to create or impose) a Lien
under any of the Material Contracts, or (v) to such counsel’s knowledge,
result in the termination, suspension or revocation of any Material
Authorization of the Company;

22

Purchase Agreement

LA\1074155.8

 

		
	 	                (viii) except as set forth on Schedule F hereto or in the Offering
Memorandum, such counsel does not know of any legal or governmental
proceedings pending to which the Company is a party or to which its
property is subject, or threatened with respect to the Company or its
property;

		
	 	                (ix) the Company is not and, after giving effect to the offering and
sale of the Notes and the application of the net proceeds thereof as
described in the Offering Memorandum, will not be, an “investment
company” as such term is defined in the Investment Company Act of 1940,
as amended;

		
	 	                (x) except as set forth on Schedule G hereto or in the Offering
Memorandum, to such counsel’s knowledge, there are no contracts,
agreements or understandings between the Company and any person granting
such person the right to require the Company to file a registration
statement under the Act with respect to any securities of the Company or
to require the Company to include such securities with the Notes
registered pursuant to any Registration Statement;

		
	 	                (xi) to such counsel’s knowledge, except as set forth on Schedule F
hereto or in the Offering Memorandum, the Company has not received any
notice of infringement of or conflict with asserted rights of others with
respect to any of the Company’s patent rights, licenses, copyrights,
know-how (including trade secrets and other unpatented and/or
unpatentable proprietary or confidential information, systems or
procedures), trademarks, service marks and trade names which has not been
resolved;

		
	 	                (xii) the Indenture complies as to form in all material respects
with the requirements of the TIA, and the rules and regulations of the
Commission applicable to an indenture which is qualified thereunder. It
is not necessary in connection with the offer, sale and delivery of the
Notes to the Initial Purchasers in the manner contemplated by this
Agreement or in connection with the Exempt Resales to qualify the
Indenture under the TIA; and

		
	 	                (xiii) no registration under the Act of the Securities is required
for the sale of the Securities to the Initial Purchasers as contemplated
by this Agreement or for the Exempt Resales assuming that: (i) each
Initial Purchaser is a QIB, (ii) the accuracy of, and compliance with,
the Initial Purchasers’ representations and agreements contained in
Section 7 of this Agreement, and (iii) the accuracy of the
representations of the Company set forth in Section 6(gg) of this
Agreement.

               Such opinion shall also include a statement that such counsel has no
reason to believe that, as of the date of the Offering Memorandum or as of the
Closing Date or the Option Closing Date, as the case may be, the Offering
Memorandum and all documents incorporated therein by reference, as amended or
supplemented, if applicable (except for the financial statements and other
financial data included therein or incorporated therein by reference, as to
which such counsel need not express any belief) contains any untrue statement
of a material fact or omits to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were
made, not misleading.

23

Purchase Agreement

LA\1074155.8

 

               The opinion of Gray Cary Ware & Freidenrich LLP described in Section
9(e)(A) above shall be rendered to you at the request of the Company and shall
so state therein. In giving such statement, Gray Cary Ware & Freidenrich LLP
may state that their opinion and belief are based upon their participation in
the preparation of the Offering Memorandum and any amendments or supplements
thereto and review and discussion of the contents thereof, but are without
independent check or verification except as specified.

          (B) You shall have received on the Closing Date and each Option Closing
Date, if any, an opinion (satisfactory to you and counsel for the Initial
Purchasers), dated the Closing Date or such Option Closing Date, as the case
may be, of John A. Cottingham, General Counsel for the Company, or of foreign
counsel to the Company with respect to certain foreign subsidiaries, to the
effect that:

		
	 	                (i) each of the Material Subsidiaries has been duly incorporated, is
validly existing as a corporation in good standing under the laws of its
jurisdiction of incorporation and has the corporate power and authority
to carry on its business as described in the Offering Document and to
own, lease and operate its properties.

		
	 	                (ii) each of the Company and its Material Subsidiaries is duly
qualified and is in good standing as a foreign corporation authorized to
do business in each jurisdiction in which the nature of its business or
its ownership or leasing of property requires such qualification, except
where the failure to be so qualified would not have a material adverse
effect on the business, prospects, financial condition or results of
operations of the Company and its Material Subsidiaries, taken as a
whole;

		
	 	                (iii) all of the outstanding shares of capital stock of each of the
Company’s subsidiaries have been duly authorized and validly issued and
are fully paid and non-assessable and, to such counsel’s knowledge, other
than as set forth on Schedule B hereto, are owned of record by the
Company, free and clear of any Lien;

		
	 	                (iv) to such counsel’s knowledge, neither the Company nor any of its
subsidiaries is in violation of its respective charter or by-laws and
neither the Company nor any of its subsidiaries is in default in the
performance of any obligation, agreement, covenant or condition contained
in any indenture, loan agreement, mortgage, lease or other agreement or
instrument that is material to the Company and its subsidiaries, taken as
a whole, to which the Company or any of its subsidiaries is a party or by
which the Company or any of its subsidiaries or their respective property
is bound;

		
	 	                (v) the execution, delivery and performance of this Agreement and
the other Operative Documents by the Company, the compliance by the
Company with all provisions hereof and thereof and the consummation of
the transactions contemplated hereby and thereby will not (i) require any
consent, approval, Material Authorization or other order of, or
qualification with, any court or governmental body or agency (except such
as may be required under the securities or Blue Sky laws of the various
states or for filings required by the Registration Rights Agreement),
(ii) conflict with or constitute a breach of any of the terms or
provisions of, or a default under, the charter or by-laws of the Company
or any of the Company’s subsidiaries or any indenture, loan agreement,

24

Purchase Agreement

LA\1074155.8

 

		
	 	mortgage, lease or other agreement or instrument to which the
Company or any of its subsidiaries is a party or by which the Company or
any of its subsidiaries or their respective property is bound and that is
material to the Company and its subsidiaries, taken as a whole, (iii)
violate or conflict with any applicable law or any rule or regulation,
or, to such counsel’s knowledge, any existing judgment, order or decree
of any court or any governmental body or agency having jurisdiction over
the Company, any of the Material Subsidiaries or their respective
properties, (iv) result in the imposition or creation of (or the
obligation to create or impose) a Lien under, any agreement or instrument
to which the Company or any of the Material Subsidiaries is a party or by
which the Company or any of the Material Subsidiaries or their respective
property is bound, or (v) to such counsel’s knowledge, result in the
termination, suspension or revocation of any Material Authorization of
the Company or any of its subsidiaries;

		
	 	                (vi) such counsel does not know of any legal or governmental
proceedings pending or threatened to which the Company or any of its
subsidiaries is or could be (with respect to threatened proceedings) a
party or to which any of their respective property is or could be (with
respect to threatened proceedings) subject, which is likely to result,
singly or in the aggregate, in a material adverse effect on the business,
prospects, financial condition or results of operations of the Company
and its subsidiaries, taken as a whole;

		
	 	                (vii) except as set forth on Schedule G hereto or in the Offering
Memorandum, to such counsel’s knowledge, there are no contracts,
agreements or understandings between the Company and any person granting
such person the right to require the Company to file a registration
statement under the Act with respect to any securities of the Company or
to require the Company to include such securities with the Notes
registered pursuant to any Registration Statement; and

		
	 	                (viii) to such counsel’s knowledge, neither the Company nor any of
its subsidiaries has received any notice of infringement of or conflict
with asserted rights of others with respect to any of the Company’s
patent rights, licenses, copyrights, know-how (including trade secrets
and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademarks, service marks and trade
names which has not been resolved and which, singly or in the aggregate,
is likely to result in a material adverse effect on the business,
prospects, financial condition or results of operations of the Company
and its subsidiaries, taken as a whole.

               Such opinion shall also include a statement that such counsel has no
reason to believe that, as of the date of the Offering Memorandum or as of the
Closing Date or the Option Closing Date, as the case may be, the Offering
Memorandum and all documents incorporated therein by reference, as amended or
supplemented, if applicable (except for the financial statements and other
financial data included therein or incorporated therein by reference, as to
which such counsel need not express any belief) contains any untrue statement
of a material fact or omits to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were
made, not misleading.

25

Purchase Agreement

LA\1074155.8

 

          The opinion of John A. Cottingham and of the foreign counsel to the
Company described in Section 9(e)(B) above shall be rendered to you at the
request of the Company and shall so state therein.

          (C) You shall have received on the Closing Date and each Option Closing
Date, if any, an opinion (satisfactory to you and counsel for the Initial
Purchasers), dated the Closing Date or such Option Closing Date, as the case
may be, of Fulbright & Jaworski L.L.P., special New York counsel for the
Company, to the effect that:

		
	 	                (i) the Notes have been duly authorized and, when executed and
authenticated in accordance with the provisions of the Indenture and
delivered to and paid for by the Initial Purchasers in accordance with
the terms of this Agreement, will be entitled to the benefits of the
Indenture and will be valid and binding obligations of the Company,
enforceable in accordance with their terms except as (x) the
enforceability thereof may be limited by bankruptcy, insolvency or
similar laws affecting creditors’ rights generally and (y) rights of
acceleration and availability of equitable remedies may be limited by
equitable principles of general applicability; and

		
	 	                (ii) the Indenture has been duly authorized, executed and delivered
by the Company and is a valid and binding agreement of the Company,
enforceable against the Company in accordance with its terms except as
(x) the enforceability thereof may be limited by bankruptcy, insolvency
or similar laws affecting creditors’ rights generally and (y) rights of
acceleration and the availability of equitable remedies may be limited by
equitable principles of general applicability.

               (f) The Initial Purchasers shall have received on the Closing Date and on
each Option Closing Date, an opinion, dated the Closing Date, of Latham &
Watkins LLP, counsel for the Initial Purchasers, in form and substance
reasonably satisfactory to the Initial Purchasers.

               (g) The Initial Purchasers shall have received, at the time this Agreement
is executed and at the Closing Date and each Option Closing Date, letters dated
the date hereof or the Closing Date or an Option Closing Date, as the case may
be, in the form and substance satisfactory to the Initial Purchasers from Ernst
& Young LLP, independent public accountants, containing the information and
statements of the type ordinarily included in accountants’ “comfort letters” to
the Initial Purchasers with respect to the financial statements and certain
financial information contained in or incorporated by reference into the
Offering Memorandum.

               (h) The Notes shall have been approved by the NASD for trading and duly
listed in PORTAL.

               (i) The Initial Purchasers shall have received a counterpart, conformed as
executed, of the Indenture which shall have been entered into by the Company
and the Trustee.

               (j) The Company shall have executed the Registration Rights Agreement and
the Initial Purchasers shall have received an original copy thereof, duly
executed by the Company.

26

Purchase Agreement

LA\1074155.8

 

               (k) The Company shall not have failed at or prior to the Closing Date or
any Option Closing Date, as the case may be, to perform or comply with any of
the agreements herein contained and required to be performed or complied with
by the Company at or prior to the Closing Date or Option Closing Date, as the
case may be.

               (l) The Initial Purchasers shall have received on the Closing Date a
certificate, dated the Closing Date, and on an Option Closing Date, if any,
dated such Option Closing Date, signed by C. Eric Winzer, in his capacity
Executive Vice President and Chief Financial Officer of the Company
substantially in the form attached hereto as Exhibit B.

     10.     Effectiveness
of Agreement and Termination. This Agreement may be
terminated at any time on or prior to the Closing Date by the Initial
Purchasers by written notice to the Company if any of the following has
occurred: (i) any change, or any development or event involving a prospective
change, in the condition (financial or other), business, properties or results
of operations of the Company and its subsidiaries taken as one enterprise
which, in the judgment of UBS, is material and adverse and makes it impractical
or inadvisable to proceed with completion of the offering or the sale of and
payment for the Notes; (ii) any downgrading in the rating of any debt
securities of the Company by any “nationally recognized statistical rating
organization” (as defined for purposes of Rule 436(g) under the Act), or any
public announcement that any such organization has under surveillance or review
its rating of any debt securities of the Company (other than an announcement

with positive implications of a possible upgrading, and no implication of a
possible downgrading, of such rating) or any announcement that the Company has
been placed on negative outlook; (iii) any change in U.S. or international
financial, political or economic conditions or currency exchange rates or
exchange controls as would, in the judgment of UBS, be likely to prejudice
materially the success of the proposed issue, sale or distribution of the
Notes, whether in the primary market or in respect of dealings in the secondary
market, (iv) any material suspension or material limitation of trading in
securities generally on the New York Stock Exchange, or any setting of minimum
prices for trading on such exchange, or any suspension of trading of any
securities of the Company on any exchange or in the over-the-counter market;
(v) any banking moratorium declared by U.S. Federal or New York authorities;
(vi) any major disruption of settlements of securities or clearance services in
the United States or (vii) any attack on, outbreak or escalation of hostilities
or act of terrorism involving the United States, any declaration of war by
Congress or any other national or international calamity or emergency if, in
the judgment of UBS, the effect of any such attack, outbreak, escalation, act,
declaration, calamity or emergency makes it impractical or inadvisable to
proceed with completion of the offering or sale of and payment for the Notes.

     If on the Closing Date or an Option Closing Date, as the case may be, any
one or more of the Initial Purchasers shall fail or refuse to purchase the
Notes which it or they have agreed to purchase hereunder on such date and the
aggregate principal amount of the Notes which such defaulting Initial Purchaser
or Initial Purchasers, as the case may be, agreed but failed or refused to
purchase is not more than one-tenth of the aggregate principal amount of the
Notes to be purchased on such date by all Initial Purchasers, each
non-defaulting Initial Purchaser shall be obligated severally, in the
proportion which the principal amount of the Notes set forth opposite its name
in Schedule A bears to the aggregate principal amount of the Notes which all
the non-defaulting Initial Purchasers, as the case may be, have agreed to
purchase, or in such other proportion as you may specify, to purchase the Notes
which such defaulting Initial Purchaser or Initial Purchasers, as

27

Purchase Agreement

LA\1074155.8

 

the case may be, agreed but failed or refused to purchase on such date;
provided that in no event shall the aggregate principal amount of the Notes
which any Initial Purchaser has agreed to purchase pursuant to Section 2 hereof
be increased pursuant to this Section 10 by an amount in excess of one-tenth of
such principal amount of the Notes without the written consent of such Initial
Purchaser. If on the Closing Date, or an Option Closing Date, as the case may
be, any Initial Purchaser or Initial Purchasers shall fail or refuse to
purchase the Notes and the aggregate principal amount of the Notes with respect
to which such default occurs is more than one-tenth of the aggregate principal
amount of the Notes to be purchased by all Initial Purchasers and arrangements
satisfactory to the Initial Purchasers and the Company for purchase of such the
Notes are not made within 48 hours after such default, this Agreement will
terminate without liability on the part of any non-defaulting Initial Purchaser
and the Company. In any such case which does not result in termination of this
Agreement, either you or the Company shall have the right to postpone the
Closing Date, or such Option Closing Date, as the case may be, but in no event
for longer than seven days, in order that the required changes, if any, in the
Offering Memorandum or any other documents or arrangements may be effected.
Any action taken under this paragraph shall not relieve any defaulting Initial
Purchaser from liability in respect of any default of any such Initial
Purchaser under this Agreement.

     11.     Miscellaneous. Notices given pursuant to any provision of this
Agreement shall be addressed as follows: (i) if to the Company to Invitrogen
Corporation, 1600 Faraday Avenue, Carlsbad, California, 92008, attention: Chief
Financial Officer and General Counsel, and (ii) if to the Initial Purchasers,
UBS Securities LLC, 299 Park Avenue, New York, New York 10171, Attention:
Syndicate Department, or in any case to such other address as the person to be
notified may have requested in writing.

     The respective indemnities, contribution agreements, representations,
warranties and other statements of the Company and the Initial Purchasers set
forth in or made pursuant to this Agreement shall remain operative and in full
force and effect, and will survive delivery of and payment for the Securities
regardless of (i) any investigation, or statement as to the results thereof,
made by or on behalf of the Initial Purchasers; the officers or directors of
the Initial Purchasers, any person controlling the Initial Purchasers, the
Company, the officers or directors of the Company, or any person controlling
the Company, (ii) acceptance of the Securities and payment for them hereunder
and (iii) termination of the Agreement.

     If for any reason the Notes are not delivered by or on behalf of the
Company as provided herein (other than as a result of any termination of this
Agreement pursuant to Section 10), the Company agrees to reimburse the Initial
Purchasers for all out-of-pocket expenses (including the fees and disbursements
of counsel) incurred by them Notwithstanding any termination of this
Agreement, the Company shall be liable for all expenses which it has agreed to
pay pursuant to Section 5(h) hereof. The Company also agrees to reimburse the
Initial Purchasers and its officers, directors and each person, if any, who
controls such Initial Purchasers within the meaning of Section 15 of the Act or
Section 20 of the Exchange Act for any and all fees and expenses (including
without limitation the reasonable fees and expenses of counsel) incurred by
them in connection with enforcing their rights under this Agreement (including
without limitation its rights under Section 8).

28

Purchase Agreement

LA\1074155.8

 

     Except as otherwise provided, this Agreement has been and is made solely
for the benefit of and shall be binding upon the Company, the Initial
Purchasers, the Initial Purchasers’ directors and officers, any controlling
persons referred to herein, the directors of the Company and their respective
successors and assigns, all as and to the extent provided in this Agreement,
and no other person shall acquire or have any right under or by virtue of this
Agreement. The term “successors and assigns” shall not include a purchaser of
any of the Securities from the Initial Purchasers merely because of such
purchase.

     This Agreement shall be governed and construed in accordance with the laws
of the State of New York.

     Each of UBS (on behalf of the Initial Purchasers) and the Company (on its
behalf and, to the extent permitted by applicable law, on behalf of its
stockholders and affiliates) waives all right to trial by jury in any action,
proceeding or counterclaim (whether based upon contract, tort or otherwise) in
any way arising out of or relating to this Agreement.

     This Agreement may be signed in various counterparts which together shall
constitute one and the same instrument.

29

Purchase Agreement

LA\1074155.8

 

     Please confirm that the foregoing correctly sets forth the agreement among
the Company, and the Initial Purchasers.

	 	 	 	 	 
	 	 	Very truly yours,
	 	 	 	 	 
	 	 	INVITROGEN CORPORATION
	 	 	 	 	 
	 	 	
By:
	 	
	 	 	 	 	

	 	 	 	 	Name: Gregory T. Lucier
	 	 	 	 	Title: President and Chief Executive Officer

UBS SECURITIES LLC

CREDIT SUISSE FIRST BOSTON LLC

By: UBS SECURITIES LLC

	 	 	 
	By:	 	

	 	 	

	 	 	
Name: Daniel H. Klausner
	 	 	
Title: Executive Director

	 	 	 
	By:	 	

	 	 	

	 	 	
Name: Richard Ng-Yow
	 	 	
Title: Managing Director

Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]